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A B S T R A C T
Background
Infantile colic is typically defined as full-force crying for at least three hours per day, on at least three days per week, for at least
three weeks. Infantile colic affects a large number of infants and their families worldwide. Its symptoms are broad and general, and
while not indicative of disease, may represent a serious underlying condition in a small percentage of infants who may need a medical
assessment. Probiotics are live microorganisms that alter the microflora of the host and provide beneficial health effects. The most
common probiotics used are of Lactobacillus, Bifidobacterium and Streptococcus. There is growing evidence to suggest that intestinal
flora in colicky infants differ from those in healthy infants, and it is suggested that probiotics can redress this balance and provide a
healthier intestinal microbiota landscape. The low cost and easy availability of probiotics makes them a potential prophylactic solution
to reduce the incidence and prevalence of infantile colic.
Objectives
To evaluate the efficacy and safety of prophylactic probiotics in preventing or reducing severity of infantile colic.
Search methods
In January 2018 we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 10 other databases and two trials registers. In
addition, we handsearched the abstracts of relevant meetings, searched reference lists, ran citation searches of included studies, and
contacted authors and experts in the field, including the manufacturers of probiotics, to identify unpublished trials.
Selection criteria
Randomised control trials (RCTs) of newborn infants less than one month of age without the diagnosis of infantile colic at recruitment.
We included any probiotic, alone or in combination with a prebiotic (also known as synbiotics), versus no intervention, another
intervention(s) or placebo, where the focus of the study was the effect of the intervention on infantile colic.
Data collection and analysis
We used standard methodological procedures of Cochrane.
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Main results
Our search yielded 3284 records, and of these, we selected 21 reports for full-text review. Six studies with 1886 participants met our
inclusion criteria, comparing probiotics with placebo. Two studies examined Lactobacillus reuteri DSM, two examined multi-strain
probiotics, one examined Lactobacillus rhamnosus, and one examined Lactobacillus paracasei and Bifidobacterium animalis. Two studies
began probiotics during pregnancy and continued administering them to the baby after birth.
We considered the risk of bias for randomisation as low for all six trials; for allocation concealment as low in two studies and unclear
in four others. All studies were blinded, and at low risk of attrition and reporting bias.
A random-effects meta-analysis of three studies (1148 participants) found no difference between the groups in relation to occurrence
of new cases of colic: risk ratio (RR) 0.46, 95% confidence interval (CI) 0.18 to 1.19; low-certainty evidence; I2 = 72%.
A random-effects meta-analysis of all six studies (1851 participants) found no difference between the groups in relation to serious
adverse effects (RR 1.02, 95% CI 0.14 to 7.21; low-certainty evidence; I2 not calculable (only four serious events for one comparison,
two in each group: meconium plug obstruction, patent ductus arteriosus and neonatal hepatitis).
A random-effects meta-analysis of three studies (707 participants) found a mean difference (MD) of -32.57 minutes per day (95% CI
-55.60 to -9.54; low-certainty evidence; I2 = 93%) in crying time at study end in favour of probiotics.
A subgroup analysis of the most studied agent, Lactobacillus reuteri, showed a reduction of 44.26 minutes in daily crying with a random-
effects model (95% CI -66.6 to -21.9; I2 = 92%), in favour of probiotics.
Authors’ conclusions
There is no clear evidence that probiotics are more effective than placebo at preventing infantile colic; however, daily crying time
appeared to reduce with probiotic use compared to placebo. There were no clear differences in adverse effects.
We are limited in our ability to draw conclusions by the certainty of the evidence, which we assessed as being low across all three
outcomes, meaning that we are not confident that these results would not change with the addition of further research.
P L A I N L A N G U A G E S U M M A R Y
Probiotics to prevent infantile colic
What was the aim of this review?
The aim of this review was to investigate if probiotics given to healthy babies prevent infantile colic, and if they are safe.
Key messages
Although probiotics make little or no difference to the occurrence of infantile colic, they may reduce crying time and there were no
safety concerns. We still require more research to work out if the onset of colic can be reduced.
What did the review study?
Infantile colic affects a large number of infants and their families worldwide. Infantile colic is a problem characterised by episodes of
inconsolable crying lasting for longer than three hours per day, for more than three days a week, for at least three weeks.
Probiotics are live bacteria that, when ingested, can be beneficial for patients. Probiotics are cheap and readily available, and there is
recent research investigating their use for this problem.
What were the main results of the review?
This review included six studies. The infants in the probiotics group were given different types of probiotics, and in different doses,
and compared to infants who were given a placebo (dummy medicine).
The review found that, compared to placebo, probiotics made little or no difference to the occurrence of infantile colic, but appeared
to reduce crying time. There was no difference in the reporting of side effects, with only four serious events reported in one large study,
and these were clinically unlikely to be linked to the taking of either of the study products.
How up-to-date was this review?
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We searched for studies that had been published up to January 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Prophylactic probiotics compared to placebo for the prevention of infantile colic
Patient or population: infants without colic
Setting: outpat ient
Intervention: prophylact ic probiot ics
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with prophylactic
probiotics
Occurrence of new
cases of colic
Measured by: Wessel/
Rome III Criteria
Follow-up: at study end
Study population RR 0.46
(0.18 to 1.19)
1148
(3 RCTs)
⊕⊕©©
Lowa
-
85 per 1000 39 per 1000
(15 to 101)
Adverse effects
Measured by: report ing
Follow-up: during study
period
Study population RR 1.02
(0.14 to 7.21)
1851
(6 RCTs)
⊕⊕©©
Lowb
-
2 per 1000 2 per 1000
(0 to 16)
Duration of crying
Measured in: m inutes
per day
Follow-up: at study end
The mean crying t ime
ranged across control
groups f rom 60 min-
utes per day to 88 min-
utes per day
The mean crying t ime in
the intervent ion group
was 32.57 minutes per
day lower
(55.60 minutes per day
lower to 9.54 minutes
per day lower)
- 707
(3 RCTs)
⊕⊕©©
Lowc
-
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io.
4
P
ro
b
io
tic
s
to
p
re
v
e
n
t
in
fa
n
tile
c
o
lic
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
9
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded two levels due to concerns regarding publicat ion bias, imprecision and very serious inconsistency (substant ial
heterogeneity: I2 = 72%).
bDowngraded two levels due to concerns regarding publicat ion bias, general risk of bias and very serious imprecision (wide
CI, which included appreciable harm; and low occurrence of events).
cDowngraded two levels due to concerns regarding publicat ion bias, imprecision and very serious inconsistency (substant ial
heterogeneity: I2 = 92%).
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B A C K G R O U N D
See Appendix 1 for definitions of some technical terms used in
this review.
Description of the condition
Infantile colic is defined as periods of inconsolable, unexplained
and incessant crying in a seemingly healthy infant that, quite un-
derstandably, leads to exhausted, frustrated and concerned parents
seeking to comfort their child (Landgren 2011).
This condition appears to be more frequent in the first six weeks
of life, occurring in 17% to 25% of newborns depending on geog-
raphy and definitions employed, with prevalence often peaking at
that point. It is important to note that without any intervention,
colic symptoms are usually below the threshold of such diagnos-
tic criteria by three months of age (Reijneveld 2001; Vandenplas
2015; Wolke 2017).
Traditionally, the definition of the condition was based on the rule
of three; that is, unexplained episodes of crying for more than
three hours per day for three days per week for at least three weeks
(Wessel 1954). Since then, a new definition has been proposed,
which refers to a clinical condition of fussing and crying for at least
one week in an otherwise healthy infant (Hyman 2006). More
recently, colic has been included under functional gastrointesti-
nal disorders (Rome IV diagnostic criteria), and the definition has
been expanded to include paroxysms of irritability and fussiness
for at least one week in an infant who has no failure to thrive
(Drossman 2016). This replaced the Rome III criteria from 2006
(Hyman 2006), which are still cited as many studies that are his-
torical still refer to these criteria. The Rome III were actually more
consistent with the previous Wessel (Wessel 1954) definition, ex-
plicitly stating that cryingmust be for three hours per day for three
days per week for one week.
In colic, flushing of the face, meteorism (excessive flatulence in
the intestinal tract with distention of the abdomen), drawing up
of the legs, and flatulence often accompany the inconsolable cry-
ing (Savino 2010a). Symptoms typically start in the second week
of life, in both breastfed and formula-fed infants, and usually re-
solve by three months of age (Lucas 1998). Generally speaking,
these symptoms are not indicative of disease, and thus hospital
admission for these infants is generally unnecessary, detrimental
and not to be encouraged (Savino 2007a). However, about 5%
of colicky, crying infants do have a serious, underlying medical
problem (Freedman 2009; Savino 2005; Savino 2007a), and there
is evidence that older children presenting with migraine are more
likely to have been babies who had experienced colic (Romanello
2013). Therefore, parents and professionals ought to bear in mind
that a medical assessment may be needed, to exclude underlying
medical conditions in need of investigation and treatment (Savino
2010a).
The aetiopathogenesis of infantile colic remains undefined and
is most likely multi-factorial. Despite the common nature of the
condition, there is a general paucity of strong evidence in this area.
It has been suggested that a number of behavioural factors (psy-
chological and social) and biological components (food hypersen-
sitivity or allergy, or both; gut micro-organisms; dysmotility) can
contribute to its manifestation (Gupta 2007). These include the
following.
• First, the immunological model, which focuses on possible
allergens, has been suggested as a cause of colic.
◦ A key allergen is cows’ milk protein in infant formula
or even mothers’ milk. Intact proteins from a mother’s diet can
sometimes cross over into the breast milk, provoking an allergic
response and symptoms of colic in her infant. Consequently, a
low-allergen maternal diet or hypoallergenic infant formula have
been proposed as a form of treatment (Hill 2005; Iacovou 2012;
Schach 2002). Shannon 1921 first described the possibility of a
relationship between infantile colic and allergens, and since then,
several studies have evaluated the possible association between
colic and food hypersensitivity (Heine 2013; Heine 2014; Hill
1995; Iacono 1991; Lothe 1982; Merras-Salmio 2013; Saps
2011).
◦ The evidence shows that about 25% of infants with
moderate or severe symptoms have cows’ milk, protein-
dependent colic (Axelsson 1986; Hill 2000; Lindberg 1999),
which improves after some days on a hypoallergenic diet
(Campbell 1989; Dupont 2010; Estep 2000; Iacono 1991;
Iacono 2005; Jakobsson 1983; Jakobsson 2000; Lothe 1989;
Savino 2001). For these infants, infantile colic could be the first
manifestation of atopic disease, and for this reason, dietetic
treatment should be one of the first therapeutic approaches
(Gupta 2007; Hall 2012; Perry 2011; Savino 2010a). Indeed,
dietary changes are particularly indicated in cases of suspected
intolerance to cows’ milk proteins (e.g. in infants with a positive
family history; eczema or onset after the first month of life; or
colic associated with other gastrointestinal symptoms, such as
vomiting or diarrhoea) (Hill 1995; Hill 2005; Jakobsson 1983;
Lucassen 2000; Savino 2014). Additionally, there is growing
evidence that colic is 25% more prevalent in the babies of
cigarette smokers and mothers who have used nicotine
replacement in pregnancy and breastfeeding, suggesting that
there is an intolerance of the nicotine itself (Milidou 2012),
which manifests in symptoms of colic.
• Second, some studies have identified lactose intolerance -
due to a relative lactase deficiency - as a possible causative factor
in infant colic (Kanabar 2001). Carbohydrate malabsorption
leads to the colonic fermentation of sugars and an increase in the
levels of hydrogen gas (Infante 2011). The rapid production of
hydrogen in the lower bowel distends the colon, sometimes
causing pain, whereas the osmotic pressures generated by lactose
and lactic acid in the colon cause an influx of water leading to
further distension of the bowel (Kanabar 2001). Although
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studies evaluating the degree of hydrogen in the breath of colicky
infants have produced inconsistent results, increases in breath
hydrogen levels have been reported (Hyams 1989; Miller 1990;
Moore 1988).
• Third, there is growing evidence that the intestinal
microbiota in colicky infants differ from those in healthy
controls, since higher levels of anaerobic bacteria, such as
coliform and Escherichia coli, and a lower concentration of
Lactobacilli have been reported in infants with colic (Savino
2010a; Savino 2013a).
◦ Evidence also shows that the microbiota of infants
with colicky symptoms contain greater levels of aerobic bacteria,
such as Heliobacter pylori (Ali 2012), and infants without colicky
symptoms have more varied types of microbiota (de Weerth
2013). There is accumulating evidence that babies who are born
by caesarean section have different intestinal microbiota
(Grönlund 1999), and this and other factors affect infant gut
colonisation. One review by Houghteling 2015 examined these
factors and the mechanisms of disease that result from disrupted
colonisation.
◦ Human milk naturally contains prebiotics; they are
defined as indigestible oligosaccharides, which could selectively
enhance the proliferation of certain probiotic bacteria in the
colon, especially Bifidobacterium species (Thomas 2010). Some
studies have failed to find a protective effect of breastfeeding on
the development of colic in breastfed infants (Clifford 2002).
However, it is unclear whether these studies compared infants
who were exclusively breastfed from birth with infants who were
exclusively artificially fed from birth, so it is still not known
whether breastfeeding has some protective effect or whether
artificial feeding compromises the infant gut microbiome in
some way. However, Savino 2013b demonstrated higher levels of
coliforms in colicky infants who were not breastfed than in those
who were breastfed or who were not colicky. Evidence also
suggests that oligosaccharide prebiotics (a mixture of galacto-
oligosaccharides and fructo-oligosaccharides) to encourage
growth of the positive bacteria in the gut may be effective
treatments for allergy and food intolerance in general
(Arslanoglu 2012), and for crying in formula-fed infants with
colic in particular (Savino 2006).
Many studies, such asDupont 2010, Savino 2007b, Savino 2010b,
and Szajewska 2013, and one Cochrane Review, Praveen 2014,
have looked or are looking at the treatment or management of
colicky symptoms and other functional gut disorders with probi-
otics and prebiotics. However, in these times of large-scale devia-
tion from the biological norms of vaginal birth (NHS Maternity
Statistics, England 2014-15), skin-to-skin contact after delivery
and exclusive breast-milk feeding in the first weeks of life (NHS
England Breastfeeding Initiation Q1 2015/16), it is easy to under-
stand how an infant’smicrobiomemay be altered from its intended
formation by the absence of these events and the unintended gut
colonisation of less favourable bacteria from the hospital, staff or
feeding equipment. It is thought that the altered microbiota may
be responsible for the colicky pain experienced by some infants,
and that receiving probiotics prophylactically might protect the
infant from that colicky pain ever occurring, by steering the tra-
jectory of microbial gut colonisation nearer to that which was in-
tended (Indrio 2014).
Of course, it is likely that colic has no single cause, and potential
multi-factorial aetiologies may exist even in a single infant with
colicky symptoms, while certainly existing in the colicky popula-
tion.
Description of the intervention
The role of aberrant gut microbiota in infant colic has resulted in
the increased study of the use of probiotics in this area (Braeggar
2011; Kukkonen 2008; Praveen 2014). Probiotics are live organ-
isms with potential health benefits; they provide resilience to bac-
terial insult and threat to the host (Rijkers 2011).Lactobacillus and
Bifidobacterium species are the organisms most commonly used as
probiotics. Associated terms include ’prebiotics’ and ’synbiotics’.
Prebiotics are indigestible food ingredients that benefit the host
by selectively stimulating favourable growth or activity, or both,
of one or more indigenous probiotic bacteria (Roberfroid 2007),
while synbiotics are products containing both probiotics and pre-
biotics and are often used. They can be delivered through tablets,
capsules, suspensions or even as dry foods or granules. As the li-
censing arrangements for probiotic preparations vary from agent
to agent and in different countries, there is a variety of specific
dosing regimens and a range of differentmethods of accessing such
agents.
There have been numerous studies around the effectiveness of sup-
plementing the already symptomatic infant’s diet with various pro-
biotics and synbiotics to reduce the symptoms of colic, but these
seem inconclusive when taken as a whole (Savino 2010b; Sung
2014; Szajewska 2013). However, evidence is building around the
effectiveness of prophylactically supplementing the newborn in-
fant with probiotics to prevent colic and other symptoms (Indrio
2014; Oozeer 2013). Additionally, evidence is accumulating on
the safety of such an intervention (Savino 2010b).
How the intervention might work
Given the growing evidence that the intestinal microbiota in col-
icky infants differs from those in healthy controls, it is proposed
that supplying probiotic bacteria can redress this balance and pro-
vide a healthier intestinal microbiota landscape. This is required
for normal gut transit and it is postulated will reduce the func-
tional symptoms associated within colic (Savino 2010a; Savino
2013a; Savino 2013b). As the evidence base suggests, common
factors impact this colonisation process, such as birth by caesarean
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section (Grönlund 1999), and it is proposed that offering probi-
otics prophylactically to all as a form of primary prevention could
offer significant benefits to the population with minimal risks.
Why it is important to do this review
As previously stated in Praveen 2014 and above, infantile colic is
a common disorder with a stressful effect on both the infant and
parent/carer; however, the pathogenesis of colic is poorly under-
stood and involves a range of risk factors. Some of the most com-
monly prescribed treatments for infant colic have been found to
be nomore effective than placebo (Garrison 2000; Lucassen 2000;
Savino 2012). It has been increasingly thought that gutmicrobiota
play an important role in the pathogenesis of colic (Savino 2007b),
and probiotic supplementation has been suggested as a treatment
for symptoms of colic in infants, although observational studies
and clinical trials have provided mixed reports on whether this is
beneficial (Savino 2010a; Sung 2012; Sung 2014). Two Cochrane
Reviews are currently underway examining the effects of probi-
otics for infantile colic (Praveen 2014) and pain-relieving agents
for the condition (Savino 2012).
Considering the impact of the condition and the increasing scope
of oral probiotics in the field of neonatology (necrotising en-
terocolitis) and paediatrics (allergic enteritis) (Baldassarre 2010;
Deshpande 2010; Deshpande 2011), as well as the relatively low
cost and easy availability of probiotics, we believe it is important
to evaluate the current evidence on probiotics as a type of pro-
phylactic therapy to prevent the onset of infant colic, in terms of
both effectiveness and safety, using the rigorous methodology of a
Cochrane Review.
Increasingly, work is being undertaken to assess and describe mi-
crobiota in the days, weeks and months after the infant’s birth;
for example, de Weerth 2013 reported the evolution of changes
in microbiota that match the course of infant colic resolving over
three months. This illustrates why it may be more effective to give
probiotics prophylactically, early in life, to prevent colic rather
than using them to try to treat it after it has occurred.
New, large-scale studies have come to light in this area of postnatal
probiotics, including Indrio 2014, which enrolled 589 infants in
a multi-centric study; Pärtty 2013a with almost 100 preterm par-
ticipants; and Kukkonen 2008, which included over 1000 infants.
It is thus timely to revisit this area and assess the potential use
of probiotics as a preventive measure for colic, which, if proven
effective, could reduce or eliminate infant and parent/carer stress
in the early weeks and months of a baby’s life.
O B J E C T I V E S
To evaluate the efficacy and safety of prophylactic probiotics in
preventing or reducing severity of infantile colic.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), including cluster and cross-
over trials.
Types of participants
Newborn infants younger than one month of age without a di-
agnosis of infantile colic at recruitment, as defined by the study.
Gestational age range from 32 weeks to term.
Types of interventions
Any probiotic, alone or in combination with a prebiotic (also
known as synbiotics), versus no intervention, another interven-
tion(s) or placebo, and where the study considered the effect on
the onset of infantile colic. We considered any dosing regimen or
frequency of intervention. The intervention was given to pregnant
women (prior to delivery at any time), lactating mothers (while
breastfeeding in the study) andnewborn infants (as defined above).
Types of outcome measures
For all proposed outcomes, we used final outcomes from the end
of the trials, and recorded the timings of these outcomes as we
planned to perform subgroup analyses if we found sufficient stud-
ies (this was not the case).
Primary outcomes
• Occurrence of new cases of colic at study end, as defined by
the Wessel criteria.
• Adverse effects, including parental depression and mental
illness, choking, bacterial infection or apparent life-threatening/
serious events (dichotomous outcome).
Secondary outcomes
• Duration of crying (post-treatment versus baseline). Data
could have been continuous (e.g. hours per day) or dichotomous
(e.g. reduction under a predefined threshold, as determined by
the study authors).
• Number of responders in each group after treatment. We
defined responders as those who experienced a decrease in the
daily, mean crying time of 50% from baseline (dichotomous
outcome).
• Frequency of crying episodes per 24 hours, where frequency
was specified in trials separately to duration of infant’s crying
(post-treatment versus baseline) (dichotomous outcome).
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• Crying time at completion in each group in minutes per
day.
• Infant sleep duration per 24 hours at seven, 14 and 21 days
(post-treatment versus baseline) (continuous outcome), or, where
it was not grouped in this way in individual trials, using a time
window of between seven and 28 days.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases and trial registers
in June 2016 and January 2018. There were no date or language
restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 12) in the Cochrane Library, which
includes the Cochrane Developmental, Psychosocial and
Learning Problems Specialised Register.
• MEDLINE Ovid (1946 to January week 3 2018).
• MEDLINE In-Process & Other Non-Indexed Citations
Ovid (searched 30 January 2018).
• MEDLINE Epub Ahead of Print Ovid (searched 30
January 2018).
• Embase Ovid (1974 to 29 January 2018).
• CINAHL EBSCOhost (Cumulative Index to Nursing and
Allied Health Literature; 1937 to 30 January 2018).
• PsycINFO Ovid (1967 to January week 4 2018).
• Science Citation Index - Expanded Web of Science (SCI-
Expanded; 1970 to 28 January 2018).
• Social Sciences Citation Index Web of Science (SSCI; 1970
to 28 January 2018).
• Conference Proceedings Citation Index - Science Web of
Science (CPCI-S; 1990 to 28 January 2018).
• Conference Proceedings Citation Index - Social Science &
Humanities Web of Science (CPCI-SS&H; 1990 to 28 January
2018).
• LILACS (Latin American and Caribbean Health Science
Information Database; lilacs.bvsalud.org/en; searched 30 January
2018).
• Cochrane Database of Systematic Reviews (CDSR; 2018, Issue
1) part of the Cochrane Library (searched 30 January 2018).
• Database of Abstracts of Reviews of Effects (DARE; 2015,
Issue 2. Final Issue) part of the Cochrane Library (searched 3
June 2016).
• Epistemonikos (limited to systematic reviews;
www.epistemonikos.org; all available years).
• WorldCat (limited to theses; www.worldcat.org; searched
30 January 2018).
• ClinicalTrials.gov (www.clinicaltrials.gov; searched 30
January 2018).
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP; apps.who.int/trialsearch;
searched 30 January 2018).
The search strategies for each source are reported in Appendix 2.
Searching other resources
Grey literature
We handsearched abstracts presented at relevant international
meetings, including the European Society for Paediatric Gastroen-
terologyHaematology andNutrition (ESPGHAN) and theNorth
American Society for Pediatric Gastroenterology, Hepatology and
Nutrition (NASPGHAN), published from their earliest availabil-
ity (2010) until the most recent meeting (2015), with the aim of
finding relevant studies not yet published in full. There is some
evidence that data from abstracts can be inconsistent with data
in published articles (Pitkin 1999). The studies that we did find
either did not meet our inclusion criteria (Criteria for considering
studies for this review), or were not sufficiently detailed for us to
assess eligibility. Therefore, because we had determined that we
would only include abstract publications if they presented suffi-
cient data on which to judge inclusion and assess quality, we have
not included any studies found in such a way.
Supplementary searching
We inspected the references of all relevant studies and reviews
for any potentially relevant studies that we may have missed, and
contacted the authors of included studies to request any missing
or incomplete data (with the exception of a prepublication copy
of the now published Baldassarre 2016 study, no responses were
received). In addition, we ran citation searches of included studies.
Personal contacts
We contacted leaders in the field to try to identify other published
and unpublished studies.
Pharmaceutical companies
We contacted the companies that produce probiotics and synbi-
otics, as well as the companies that produce medication and for-
mula preparations, as per the Background section, to search for
any other relevant ongoing and unpublished studies.
Data collection and analysis
Selection of studies
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Having collated references and removed duplicates, two review
authors (MG and SSCB) independently screened titles, abstracts
and full reports for eligibility against the inclusion criteria (see
Criteria for considering studies for this review). Specifically, they
undertook the following tasks.
• Merged search results using reference management software
and removed duplicate records of the same report.
• Examined titles then abstracts, and removed any records
that did not meet the inclusion criteria.
• Retrieved the full texts of potentially relevant reports.
• Linked together multiple reports of the same study.
• Examined full-text reports to determine whether studies
met the eligibility criteria.
• Corresponded with investigators, when appropriate, to
clarify study eligibility.
• At all stages, noted reasons for inclusion and exclusion on a
study-flow spreadsheet, and resolved any disagreements through
consensus.
• Made final decisions on study inclusion, resolving any
discrepancies by discussion until a consensus was reached and
involving a third review author (GT) if needed.
• Proceeded to data collection.
Our selection process has been included in a PRISMA diagram
(Moher 2009). See Figure 1.
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Figure 1. Study flow diagram. RCT: randomised controlled trial.
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Data extraction and management
We developed a data extraction form a priori, as per the recom-
mendations in theCochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a), and piloted the form on the first two
RCTs to ensure it was fit for purpose. We extracted the following
information.
• Characteristics of participants: source of participants,
inclusion and exclusion criteria, total number at baseline, total
number at completion, setting, definition of colic applied,
diagnostic criteria applied, type of feeding (breastfeeding,
formula feeding), age at onset of colic, age at commencement of
intervention and evaluation of potential effect modifiers (e.g.
age, gender).
• Interventions and controls: number of groups,
intervention(s) applied, frequency and duration of treatment,
total number of treatments and permitted cointerventions.
• Methods: study design and duration, sequence generation,
allocation concealment, blinding of outcome assessors and
evaluation of success of blinding.
• Outcomes: outcomes assessed, definitions used, values of
means and standard deviations (SD) at baseline and at time
points as defined by the study protocol (or change from baseline
measures, if given).
• Results: measures at end of protocol, follow-up data
(including means and SDs, standard errors or confidence
intervals (CI) for continuous data, and summary tables for
dichotomous data), withdrawals and losses to follow-up.
• Other: references to other relevant studies, points to follow-
up with the study authors, comments from the study authors,
key conclusions from the study (by the study authors) and other
comments from the review authors.
Two review authors (MG and GT) independently extracted the
data using the data extraction form. A third review author (MRT)
resolved any disagreements. We collated the data in the latest ver-
sion of Review Manager 5 (RevMan 5) (Review Manager 2014).
Assessment of risk of bias in included studies
Two review authors (MG and SSCB) independently evaluated
each study for risk of bias, using the criteria recommended in
the Cochrane Handbook for Systematic Reviews of Interventions (
Deeks 2011; Higgins 2011b), and set out in Appendix 3, for the
following domains: sequence generation; allocation concealment;
blinding of parents and health professionals; blinding of outcome
assessment; incomplete outcome data; selective outcome reporting
and other potential threats to validity. We judged each domain
as being at low, high or unclear risk of bias. We compared the
judgements and discussed and resolved any inconsistencies in the
assessments. A third review author (MRT) was available to resolve
any persisting disagreements.
Measures of treatment effect
Dichotomous data
Wepresented dichotomous data as risk ratios (RR), since the effects
of the RR are readily understood (Walter 2000). We reported all
RRs with their associated 95% CIs and probability values (when
possible).
Continuous data
When all studies use the same measurement scale, we calculated
mean differences (MD) and presented these with 95% CI. For
methods to handle studies that use different measurement scales,
see protocol, Banks 2016, and Table 1.
When necessary, we calculated effect estimates from P values, t
statistics, analysis of variance (ANOVA) tables or other statistics,
as recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (Deeks 2011), but only in situations when the
raw data (MD or standardised mean difference (SMD)) were not
directly available in the study publications.
For this analysis, we used, according to need, either change scores
or final values without combining them.
If both continuous and dichotomous data were available for an
outcome,we included only the continuous outcome in the primary
analysis.
Unit of analysis issues
Cluster-randomised studies
We did not encounter any cluster-randomised trials. See protocol,
Banks 2016, and Table 1 for methods to handle such studies in
future updates of this review.
Studies with multiple treatment arms
In the primary analysis, we combined results across all eligible in-
tervention arms and compared them with the combined results
across all eligible control arms (another intervention(s) or placebo),
and made single, pair-wise comparisons. Where such a strategy
prevented investigation of potential sources of heterogeneity, we
analysed each type separately (against a common control group:
placebo), but divided the sample size for common comparator
arms proportionately across each comparison (Higgins 2011b).
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This simple approach allowed the use of standard software (in-
cluding Review Manager 2014) and prevented the inappropriate
double counting of participants.
Cross-over studies
In randomised cross-over studies, participants receive each inter-
vention sequentially, in a random order. Cross-over studies usually
contain a washout period, which is a stage after the first treatment
but before the second treatment, where time is given for the ac-
tive effects of the first treatment to wear off before the new treat-
ment begins in order to reduce the carry-over effect (where the
first treatment affects the second). The risk of a carry-over effect is
a concern in cross-over studies and especially for this review given
the nature of the interventions we assessed. For this review, we
only included data from the first treatment period from cross-over
studies.
Dealing with missing data
Where data were missing, we contacted the corresponding authors
of included studies requesting them to supply any unreported data;
details are given in the Characteristics of included studies table.
For all outcomes in all studies, we carried out analyses as far as
possible on an intention-to-treat basis; that is, we attempted to
include all participants randomised to each group in the analyses,
and we analysed all participants in the group to which they were
allocated regardless of whether or not they received the allocated
intervention.
Formissing continuous data, we estimated SD fromother available
data, such as standard errors, or we imputed them using the meth-
ods suggested in Higgins 2011b. We conducted analyses based on
participants completing the trial, in line with available-case anal-
ysis; this assumed that missing data were at random. If there was
a discrepancy between the number randomised and the number
analysed in each treatment group, we calculated and reported the
percentage lost to follow-up in each group.
When it was not possible to obtain missing data, we recorded this
on the data collection form, reported it in the ’Risk of bias’ table,
and discussed the extent to which the missing data could alter
the results and hence the conclusions of the review. For included
studies, we noted levels of attrition. We planned to explore the
impact of including studies with high levels of missing data in
the overall assessment of treatment effect by conducting sensitivity
analyses (Banks 2016), but as there were few studies in our analysis,
this was not possible. See Table 1.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important participant characteristics between trials (e.g. age)
and trial characteristics (e.g. randomisation, concealment, blind-
ing of outcome assessment, losses to follow-up, treatment type,
cointerventions).
We employed a Chi2 test of homogeneity, with a 10% level of sig-
nificance, to determine the strength of evidence that heterogeneity
was genuine.
In addition, we assessed statistical heterogeneity by examining the
I2 statistic (Deeks 2011), a quantity that describes the proportion
of variation in point estimates that is due to variability across
studies rather than sampling error. We interpreted the I2 statistic
as suggested in Deeks 2011:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity and
• 75% to 100%: suggests considerable heterogeneity.
Assessment of reporting biases
Tominimise publication bias, we attempted to obtain the results of
any unpublished studies, in order to compare the results extracted
from published journal reports with the results obtained from
other sources (including correspondences).
We were unable to assess reporting biases using funnel plots due to
the small number of included studies. See Banks 2016, and Table
1.
Data synthesis
When interventions were similar in terms of type of intervention,
type of outcome assessed and type of colic, we grouped the studies
and synthesised their results in a meta-analysis. We presented re-
sults for each combination of probiotic intervention, assessed out-
come and colic type, with the exception of those studies for which
there were no data. For instance, when two or more studies as-
sessed the effects of prophylactic probiotic use in otherwise healthy
infants with colic and both measured daily crying, we performed
a meta-analysis of the results. Because we assumed that clinical
heterogeneity was very likely to impact on our results, given the
wide breadth and types of interventions included, we combined
the studies using a random-effects model, regardless of statisti-
cal evidence of heterogeneity of effect sizes, calculating individ-
ual treatment effects and assigning weight using inverse variance.
We used these calculations to produce a pooled effect, which we
presented in a forest plot. We carried out statistical analysis using
RevMan 5 (Review Manager 2014). When data were insufficient,
we provided a narrative description of the results.
’Summary of findings’ tables
We assessed the overall certainty of the evidence using theGRADE
approach (Guyatt 2008). The GRADE approach appraises the
certainty of a body of evidence based on the extent to which one
can be confident that an estimate of effect, or association, reflects
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the item being assessed. RCTs start as high-certainty but may be
downgraded due to risk of bias (methodological quality), indirect-
ness of evidence, unexplained heterogeneity, imprecision (sparse
data) and publication bias. Two review authors (SB and MG) in-
dependently assessed the overall certainty of the evidence for each
outcome after considering each of these factors and graded them
as follows.
• High certainty: we are very confident that the true effect lies
close to that of the estimate of the effect.
• Moderate certainty: we are moderately confident in the
effect estimate: the true effect is likely to be close to the estimate
of the effect, but there is a possibility that it is substantially
different.
• Low certainty: our confidence in the effect estimate is
limited: the true effect may be substantially different from the
estimate of the effect.
• Very low certainty: we have very little confidence in the
effect estimate: the true effect is likely to be substantially
different from the estimate of effect.
We reported our ratings for the outcomes listed below in Summary
of findings for the main comparison, which we constructed using
GRADEpro GDT (GRADEpro GDT).
• Occurrence of new cases of colic at study end.
• Adverse effects, including parental depression and mental
illness, choking, bacterial infection or apparent life-threatening
events/serious events (dichotomous outcome) during study
period.
• Duration of crying at study end.
Subgroup analysis and investigation of heterogeneity
Large numbers of subgroup analyses may lead to misleading con-
clusions (Oxman 1992; Yusuf 1991).We conducted the following
subgroup analyses, when possible.
• Type of feeding (artificially fed babies versus breastfed
babies).
• Preterm babies (pre-37 weeks’ and pre-33 weeks’ gestation)
versus term babies (born between 37 and 43 weeks’ gestation).
• Antenatal starting of probiotics for pregnant women with
continuation postnatally versus postnatal probiotics (see
Differences between protocol and review).
• Type of probiotic (or combination of probiotic with
prebiotic, also known as ’synbiotic’).
Due to the heterogeneity of primary study designs and reported
outcomes, such analysis were limited, with data not reported to
explore many of these outcomes.
We were unable to conduct our other, preplanned subgroup anal-
yses (Banks 2016), due to a lack of data. See Table 1.
Sensitivity analysis
We conducted a sensitivity analysis to determine whether find-
ings were sensitive to the choice of meta-analysis model used, by
comparing results from the fixed-effect model with those of the
random-effects model. We were unable to conduct our other, pre-
planned sensitivity analyses (Banks 2016), due to a lack of data.
See Table 1.
R E S U L T S
Description of studies
Results of the search
Our Electronic searches, conducted up to January 2018, retrieved
3257 records. We identified a further 27 records by searching
references. After removing duplicates, we screened the titles and
abstracts of the remaining 2809 records for eligibility, discarding
those that were clearly irrelevant. We selected 21 records for full-
text review (See Figure 1). Of these, we excluded 12 studies (see
Characteristics of excluded studies) and included six studies (see
Characteristics of included studies table). We found no studies
awaiting classification or ongoing studies.
Included studies
Study design
This review included nine reports describing six RCTs (Baldassarre
2014; Indrio 2008; Indrio 2014; Kukkonen 2008; Pärtty 2013a;
Vlieger 2009).
Participants
The studies included 1886 participants. Participants were preg-
nant women, breastfeeding mothers or newborn babies, depend-
ing on study design.
Interventions
In two studies pregnant women began the intervention at 36
weeks’ gestation and continued until birth (Baldassarre 2014;
Kukkonen 2008). In one of these two studies, Baldassarre 2014,
themothers, whowere all breastfeeding, continued taking the pro-
biotic or placebo for four weeks after the baby was born; in the
other study, Kukkonen 2008, the infants were then given the inter-
vention probiotic or placebo. In one study, Pärtty 2013a, preterm
infants of gestational age 32 (+ 0) to 36 (+ 6) weeks began the in-
tervention on day one of life. In three studies, formula-fed infants
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began the intervention either from birth (Indrio 2014), or within
the first week of life (Indrio 2008; Vlieger 2009).
The duration of the interventions varied from 30 days (Indrio
2008) to six months (Kukkonen 2008).
Two studies used a synbiotic instead of just probiotic (Kukkonen
2008; Vlieger 2009).
Control/comparisons
All studies used placebo as the control. No studies employed a no
intervention group or other interventions.
Outcomes
The specific outcomes selected for the various studies ranged from
breast milk analysis to infant stool analysis, infections to regurgi-
tation, and from GP visits, hospital admissions and days of work
lost, to our main search outcome of crying or colicky symptoms.
Colic was defined in a number of ways, including using Rome
III (Hyman 2006) criteria (Baldassarre 2014; Indrio 2008; Indrio
2014), and the Wessel (Wessel 1954) criteria (Kukkonen 2008;
Pärtty 2013a). One study used incidence of colic as an outcome
measure, but authors were not specific about how this was assessed
(Vlieger 2009).
Funding
Four of the studies were funded by industry (Indrio 2008; Indrio
2014; Pärtty 2013a; Vlieger 2009). In two studies, industry sup-
plied the interventional product but had no other involvement in
the study (Indrio 2008; Indrio 2014), and in two studies indus-
try funded the authors’ salary (Pärtty 2013a; Vlieger 2009). See
Characteristics of included studies table for further information.
Excluded studies
We excluded 12 studies (from 12 reports). Five studies were not
RCTs (Di Mauro 2013; Mommaerts 2011; Olivares 2011; Pärtty
2013b; Wade 2001); four studies did not investigate colic (Cekola
2015;Garofoli 2014;Hoy-Schulz 2016; Savino 2015); two studies
did not administer probiotics prophylactically (Simone 2014;
Szajewska 2013); and one study started the intervention in infants
from fourmonths of age, so was not prophylactic by our definition
(Weizman 2006). See the Characteristics of excluded studies table.
Risk of bias in included studies
The results of our ’Risk of bias’ assessment for the included studies
is summarised in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Five studies described an adequate method of random alloca-
tion of participants to intervention groups (Indrio 2008; Indrio
2014; Kukkonen 2008; Pärtty 2013a; Vlieger 2009), so we rated
these studies at low risk of bias on this domain. For one study,
Baldassarre 2014, this was unclear, but reported as adequate in the
full manuscript (Baldassarre 2016), so we rated this study at low
risk of bias.
Allocation concealment
We considered allocation concealment to be described adequately
in one study, which we rated at low risk of bias on this domain
(Pärtty 2013a). Additionally, the lead authors of three studies re-
sponded to a request for further information and confirmed ad-
equate allocation concealment, so we rated these studies at low
risk of bias (Baldassarre 2014; Indrio 2008; Indrio 2014). The re-
maining two studies either did not describe or mention allocation
concealment, so we considered those studies at unclear risk of bias
on this domain (Kukkonen 2008; Vlieger 2009).
Blinding
We rated five studies at low risk of performance bias and detection
bias because they described adequate methods for blinding (Indrio
2008; Indrio 2014; Kukkonen 2008; Pärtty 2013a; Vlieger 2009).
We also rated the remaining study by Baldassarre 2014 at low risk
of performance and detection bias as we were able to confirm ad-
equate blinding from the full, published manuscript (Baldassarre
2016).
Incomplete outcome data
We judged all six studies at low risk of attrition bias because drop-
outs were either balanced across treatment groups, with similar
reasons for withdrawal, or there were few dropouts (Baldassarre
2014; Indrio 2008; Indrio 2014; Kukkonen 2008; Pärtty 2013a;
Vlieger 2009).
Selective reporting
We judged four studies at low risk of reporting bias because they
discussed the key declared outcomes from their methods, includ-
ing adverse outcomes and these matched those reported in trial
registration records or protocols (Indrio 2008; Indrio 2014; Pärtty
2013a; Vlieger 2009). Two studies did not state the outcome of
investigating colic in the trial registration record and were at high
risk of reporting bias (Baldassarre 2014; Kukkonen 2008)
Other potential sources of bias
Because of the nature of the evidence contained within these stud-
ies, and the claims for one product or intervention over another
in such a vulnerable population, we considered any involvement
by the companies supplying or manufacturing the intervention
product in the conduct of the studies or the writing up of results,
to trigger a rating of high risk of other bias. Two studies declared
no financial involvement with industry, whether by provision of
experimental product or by direct financial support for the work,
and so we rated them at low risk of other bias (Baldassarre 2014;
Kukkonen 2008). The remaining four studies stated that theywere
supported by the manufacturers of the intervention, or received
support from the manufacturers, or both, and so we rated them at
high risk of other bias (Indrio 2008; Indrio 2014; Pärtty 2013a;
Vlieger 2009).We contacted the authors to confirm that there was
no such involvement and thereby downgraded the judgement, but
received no responses to our requests. None of the studies appeared
to have any other potential sources of bias other than industry
funding.
Effects of interventions
See:Summaryof findings for themain comparisonProphylactic
probiotics compared to placebo for the prevention of infantile
colic
See Characteristics of included studies table.
All six included studies compared probiotics to placebo.No studies
employed a no intervention group or another intervention. Below,
we presented the results of the main analyses for this comparison
by outcome, followed by the results of key subgroup analyses based
on participants and interventions. For the purposes of readability,
we reported the results of sensitivity analyses using the fixed-effect
model directly after the results of analyses using the random-effects
model.
We summarised the evidence for ’occurrence of new cases of colic’,
’adverse effects’ and ’crying time’ in Summary of findings for the
main comparison. We downgraded our certainty in the evidence
from all analyses to low, due to concerns with imprecision, sub-
stantial unexplained statistical heterogeneity and low event num-
bers within adverse effects. It is worth noting that for all these
analyses, we downgraded the certainty of the evidence due to con-
cerns with publication bias. This was based on other reviews cited
in the field on infantile colic that included negative trials. We felt
that with the small number of individually positive studies in this
review, there was a pervasive risk, hence leading to this judgement.
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Probiotics versus placebo
All six included studies compared probiotics to placebo (
Baldassarre 2014; Indrio 2008; Indrio 2014; Kukkonen 2008;
Pärtty 2013a; Vlieger 2009). Two studies used probiotics with
prebiotics, so-called synbiotics (Kukkonen 2008; Vlieger 2009).
Primary outcomes
Occurrence of new cases of colic
We conducted a random-effects meta-analysis of three studies
with 1148 participants (Baldassarre 2014; Kukkonen 2008; Pärtty
2013a), and found no significant difference between the two
groups in relation to the occurrence of new cases of colic (RR 0.46,
95% CI 0.18 to 1.19; Analysis 1.1; Figure 3; low-certainty evi-
dence, downgraded twice due to concerns with publication bias,
imprecision and very serious inconsistency; Summary of findings
for the main comparison). In a sensitivity analysis using the fixed-
effect model, we found a significant difference in favour of probi-
otics (RR 0.58, 95% CI 0.38 to 0.90; Analysis 1.2). This incon-
sistency between the two models suggests statistical heterogeneity,
and is consistent with the I2 statistic, which was high at 72%. We
were unable to investigate the causes of this heterogeneity further,
as originally planned (Banks 2016), due to the limited reported
data.
Figure 3. Forest plot of comparison: 1 Probiotic preparation versus placebo, outcome: 1.1 Occurrence of
new cases of colic: random-effects model.
Adverse effects
We conducted a meta-analysis of all six studies (Baldassarre 2014;
Indrio 2008; Indrio 2014; Kukkonen 2008; Pärtty 2013a; Vlieger
2009), and found no difference between the groups in relation to
serious adverse effects (RR 1.02, 95% CI 0.14 to 7.21; 1851 par-
ticipants; Analysis 1.3; low-certainty evidence, downgraded twice
due to concerns with publication bias, general risk of bias and
very serious inconsistency; Summary of findings for the main
comparison). It is worth noting that there were just four events re-
ported across all six studies, all in the same study with two in each
condition. These were meconium plug obstruction, patent ductus
arteriosus and neonatal hepatitis. This prevented calculation of
the I2 statistic. This same study reported all minor events that oc-
curred, with similar rates of neonatal morbidity (probiotic versus
prebiotic: jaundice: 11 versus 6 events; hypoglycaemia: 14 versus
11 events; infection 11 versus 24 events; oxygen supplementation:
11 versus 18 events). These were all appropriate background rates
for such events in a normal neonatal population and also unlikely
related to either study arm.
Secondary outcomes
Duration of crying
We conducted a random-effectsmeta-analysis of three studies with
707 participants (Indrio 2008; Indrio 2014; Vlieger 2009), and
found a difference between the two groups in favour of probiotics,
for crying time (MD -32.57 minutes per day, 95% CI -55.60
to -9.54; Analysis 1.4; Figure 4; low-certainty evidence, down-
graded twice due to concerns with publication bias, imprecision
and very serious inconsistency; Summary of findings for the main
comparison). We found similar results when using a fixed-effect
model in a sensitivity analysis (MD -32.57, 95%CI -55.6 to -9.54;
Analysis 1.5). The I2 statistic for both analyses was 93%, with a
significant Chi2 result, suggesting considerable statistical hetero-
geneity for which we subsequently downgraded the certainty of
the evidence in the GRADE analysis.
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Figure 4. Forest plot of comparison: 1 Probiotic preparation versus placebo, outcome: 1.4 Crying time:
random-effects model (minutes/day).
Single study results
Kukkonen 2008 compared a mixture of four probiotic species
(Lactobacillus rhamnosus GG, LC705, Bifidobacterium vreve Bb99,
Propionibactterium freudenreichii ssp shermanii) with placebo and
found no significant difference between the groups in relation to
infantile colic, defined as excessive crying in both groups.
Pärtty 2013a compared placebo with Galacto-oligosaccharide and
with Lactobacillus rhamnosus GG, and found fewer excessive criers
in both intervention groups compared with the placebo group (P
= 0.02). Only one other study used Lactobacillus rhamnosus, but
it was mixed with other probiotics (Kukkonen 2008).
Vlieger 2009 compared prebiotic formula (containing Lactobacil-
lus paracasei, Paracasei andBifidobacterium animalis, Lactis) with
the same formula without probiotics and found no difference be-
tween the groups in relation to crying time. Infants who were not
going to be breastfed were started on this milk within one week of
birth and continued to receive it for three months. This study was
designed to determine whether probiotic intervention was safe. It
found no difference between the prebiotic and placebo groups in
relation to mean crying time (1.8 hours per day) at three months
of age.
Baldassarre 2016 (an additional report of Baldassarre 2014)
compared multi-strain probiotics (Lactobacillus paracasei, Plan-
tarum, Acidophilus,Delbruieckii subsp. bulgaricus,Bifidobacterium
longum,Breve,Infantis,Streptococcus thermophiles) with placebo and
found that colic was less frequent in the probiotic group compared
to the placebo group (P = 0.007).
No studies reported data on our other secondary outcomes: dura-
tion of crying; number of responders; frequency of crying episodes
per 24 hours; infant sleep duration per 24 hours.
Subgroup analyses
Therewasmuch heterogeneity in the included studies, primarily in
relation to the species of probiotic given and the age of infants who
received it. Subgroup consideration is shown below, highlighting
the relevant meta-analysis where there was scope to complete this.
It is worth noting that, given the small number of studies included
in the review, these analyses were comprised of only a few studies
or, in some cases, a single study. Given the clinical heterogeneity,
this is a necessary set of analyses, but must be interpreted with
caution.
Type of feeding
Two studies looked at the effects of probiotics for artificially fed or
breastfed babies (or both) (Indrio 2014; Pärtty 2013a). We were
unable to conduct a meta-analysis due to the different outcome
measures reported between these studies. Indrio 2008 compared
10 artificially fed babies receiving probiotics with 10 artificially
fed babies receiving placebo. Crying time in preterm infants fed
formula and supplemented with placebo was recorded as 88 (SD
16) minutes per day, compared to 32 (SD 6) minutes per day
in formula-fed infants supplemented with probiotics, giving a re-
duction of 56 (SD 16) minutes per day or 71.8%. Pärtty 2013a
usedmixed probiotics (31 infants) and placebo (32 infants) groups
made up of breastfeeding babies, mixed-fed babies and artificially
fed babies. This study rated babies as excessive criers if their total
crying time exceeded three hours per day, causing clinical concern
but without medical causes during the study visits in months one
and two (modified Wessel criteria: Wessel 1954), resolving by six
months of age. Babies who did not meet this criterion were la-
belled “contented”. Just 22% of babies in the probiotic group were
categorised as excessive criers compared with 56% of babies in the
placebo group. The paper did not record crying time and the study
author did not respond to our requests for more information.
Preterm versus term babies
Two studies looked at the effects of probiotics for preterm babies
(gestational age from 32 (+ 0) weeks to 36 (+ 6) weeks) for 30 days
(Indrio 2008) and 60 days (Pärtty 2013a). Indrio 2008 chose to
supplement the babies with Lactobacillus reuteri (1 × 108 colony-
forming unit (CFU) per day), and Pärtty 2013a with Lactobacillus
rhamnosus (1 × 109 CFU per day from birth to day 30, and twice
per day from days 31 to 60). Both studies recruited at birth. Indrio
2008 entered the babies into the study between days one and three
of life whereas Pärtty 2013a entered babies into the study between
days three and five of life. Data were not presented in a consistent
format for these studies to facilitate meta-analysis.
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Two studies looked at the effects of probiotics on term babies
(Indrio 2014; Kukkonen 2008). We were unable to conduct a
meta-analysis of the results from these studies because of the het-
erogeneity of both the population and the intervention. Indrio
2014 looked at healthy infants given probiotics within the first
week of life and for 90 days. Kukkonen 2008 looked at infants at
increased risk of allergy who were supplemented with probiotics
from birth, after the mother had been given probiotics from 36
weeks’ gestation until birth. Duration of crying time for partic-
ipants in Indrio 2014 was 38 minutes per day in the probiotic
group versus 71 minutes per day in the placebo group at study
end. Kukkonen 2008 claimed no difference in rates of infantile
colic, defined as four or more hours of crying per day on at least
three days per week, between the probiotic and placebo groups
(4% occurrence in each group). They also defined another out-
come based on a definition of a ’less-frequent crying group’ (once
or twice per week), which was 10% in both probiotic intervention
and placebo participants on completion. Kukkonen 2008 was set
up to look at long-term safety and impact on infection, rather than
intestinal comfort, whereas Indrio 2014 was looking for a preven-
tive measure for constipation, colic and intestinal discomfort.
An analysis of two studies with 687 term infants (Indrio 2014;
Vlieger 2009), comparing probiotics and placebo, found no dif-
ference between the groups (MD -20.65 minutes per day, 95% CI
-47.23 to 5.92; Analysis 1.6; moderate-certainty evidence, down-
graded once due to serious inconsistency concerns).
Antenatal starting of probiotics for pregnant women with
continuation postnatally versus postnatal probiotics
Two studies with 1085 participants included probiotic supple-
ments given to pregnant women from 36 weeks’ gestation as the
first part of the intervention (Baldassarre 2014; Kukkonen 2008).
Baldassarre 2014 described colic as being more frequent in the
placebo group than in the probiotic group (RR 4; Chi2 = 7.2). A
logistic regression analysis showed the only factor with significant
impact on colic was the mothers’ probiotic consumption. The re-
sults of Kukkonen 2008 showed no significant difference between
the groups in relation to infantile colic, defined as excessive crying
in both groups. We conducted a random-effects meta-analysis for
our primary outcome, occurrence of colic, and found no differ-
ence between groups (RR 0.54, 95% CI 0.13 to 2.20; Analysis
1.7). Data were not available to allow subgroup analysis for our
other outcomes.
Type of probiotic
We found two studies with 574 participants comparing one spe-
cific probiotic, Lactobacillus reuteri, to placebo (Indrio 2008;
Indrio 2014). We conducted a random-effects meta-analysis and
found a significant reduction in crying time in favour of the probi-
otic group (MD-44.26minutes per day, 95%CI -66.60 to -21.93;
574 participants; Analysis 1.8; Figure 5; moderate-certainty evi-
dence, downgraded once due to serious inconsistency). We found
similar results when we used a fixed-effect model in a sensitivity
analysis (MD -40.53 minutes per day, 95% CI -46.53 to -34.52;
Analysis 1.9; Figure 6). However, both studies looked at different
patient groups: Indrio 2008 included preterm infants and Indrio
2014 included term infants.
Figure 5. Forest plot of comparison: 1 Probiotic preparation versus placebo, outcome: 1.7 Mean crying time
at study end: random-effects model.
Figure 6. Forest plot of comparison: 1 Probiotic preparation versus placebo, outcome: 1.8 Mean crying time
at study end: fixed-effect model.
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D I S C U S S I O N
Summary of main results
The prophylactic use of probiotics in the prevention of infantile
colic has been increasingly studied, with four of the six studies
(838 participants) included in this review published within the
last four years. Below, we summarised our findings.
• One meta-analysis of only three studies (1148 infants) that
investigated the primary outcome of ’occurrence of new cases of
colic’ found no difference between the groups, despite their
being 40% less cases of infantile colic in the probiotic group
(low-certainty evidence, downgraded two levels for very serious
inconsistency).
• The primary outcome of ’serious adverse effects’ was
reassuringly low, although this was limited to the time period in
which the probiotics were administered, and only one study
reported minor events (low-certainty evidence, downgraded two
levels due to very serious imprecision).
• One meta-analysis of three studies (702 infants) found a
reduction in the secondary outcome of ’crying time at
completion in each group’ (low-certainty evidence, downgraded
two levels due to very serious inconsistency), as did a subgroup
analysis for the specific strain of Lactobacillus reuteri in two
studies (574 infants).
Overall completeness and applicability of
evidence
The completeness and applicability of the evidence was hampered
by several issues. There was significant clinical heterogeneity. As
with other reviews of probiotics, the range of species used as a pro-
biotic raised a clinical problem in terms of applying the evidence
in practice. Additionally, the study population varied across the
studies, including both preterm and term infants, breastfeeding
and bottle feeding and studies that started prior to delivery and
postdelivery, with some administering the probiotic only to the
mother before and after birth (breastfeeding infants) and some to
the mother before birth and the infant directly after birth.
The lack of reporting the primary outcome of the occurrence of
colic was a major issue with the completeness of the evidence. As
these studies were focused on the prophylactic use of probiotics
to prevent colic, not reporting the onset of colic using established
diagnostic criteria were a significant issue that, although clearly
widespread, prevented the use of the results. Reassuringly, five of
the six studies defined colic similarly using Rome III or Wessel
criteria (although not necessarily reporting data on this outcome);
however, one study did not clarify the definition (this study did not
give data for this outcome either, so this did not impact analysis).
This may become a greater concern in the future as Rome IV
signals a significant shift in diagnostic criteria (see below).
Another issue to consider was the time point at which the crying
outcome was measured, which varied from 30 days to 90 days.
This heterogeneity further limited the clinical relevance and valid-
ity of the result, which was further compounded by the paucity of
evidence from low- and middle-income countries. Given the ac-
cepted issues in the field with the self-limiting nature of colic and
subjective problems with its assessment, this may represent a lack
of need for such research in these areas, but nevertheless limits the
ability to apply such findings in those settings. Altogether, these
issues limit the overall strength and utility of the results.
The final issue was the reporting of safety. While most studies
commented about the absence of serious adverse effects, only one
gave details on these and minor adverse effects in a manner that
allowed consideration of the significance of these findings to the
evidence base. It is vital to have detailed information in this area.
Quality of the evidence
We thoroughly reviewed the studies for results, and assessed their
risks of bias. We considered the evidence at relatively low risk of
bias. A note of caution in the interpretation of these results was
that four of the six included studies received financial support from
industry, including milk manufacturers or the makers of the pro-
biotic used. This was the one area correspondingly noted to show
high risk of bias in the assessment as the review authors judged
that without full justification and explanation regarding the nature
of such funding, a significant risk existed. Further independent
studies would be helpful.
The issue regarding the choice of outcomes, discussed above under
Overall completeness and applicability of evidence, was also key to
the certainty of the evidence. This led to the GRADE certainty of
evidence being impacted by a lack of evidence on this appropriate
primary outcome.
The results of our GRADE analysis revealed low-certainty evi-
dence for the two primary outcomes, occurrence of colic, down-
graded twice due to unexplained statistical heterogeneity, and ad-
verse effects, downgraded twice due to wide CI and low event
numbers. The evidence for the secondary outcome of crying time
was also low due to substantial statistical heterogeneity.
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The final issue of note was the time to follow-up. Similar to other
reviews on colic, there was a range of times tomeasuring outcomes,
from one month to three months. This could limit the generalis-
ability or at least predictions of prognosis from this evidence.
Potential biases in the review process
We conducted comprehensive searches, including extensive
searches of the grey literature, to identify all relevant studies. How-
ever, it was apparent that some included studies did not clearly
describe themselves as aiming to prevent colic, even though they
reported this outcome within the text. As this became apparent
in screening, while we were very cautious, it is possible that some
trials may have been missed.
To avoid bias, two review authors (MG, SSCB) independently
evaluated study eligibility, extracted data and assessed risk of bias;
on twooccasions, we resolved initial disagreements about inclusion
or exclusion with another member of the team (GTO), in line
with our protocol (Banks 2016). One of the excluded trials was
completed by a previous collaborator of this team (Savino 2015).
However, he had no involvement in the current review.
There were no other potential biases.
Agreements and disagreements with other
studies or reviews
We found no previous systematic review investigating the prophy-
lactic use of probiotics for infantile colic.
There are outstanding reviews for the treatment of colic, Praveen
2014, and pain-relieving agents for colic, Savino 2012, both of
which are still at protocol stage within Cochrane.
One systematic review using the high-quality network meta-anal-
ysis method investigated one of the preparations studied in this
review (Lactobacillus reuteri) and also found reductions in crying
time when treating colic (Gutiérrez-Castrellón 2017).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is limited evidence that prophylactic probiotics are more
effective in preventing infantile colic than placebo or no interven-
tion. There is some evidence that they may reduce key outcomes,
such as crying time and evidence demonstrating a lack of adverse
effects. The overall certainty of the evidence and strength of these
conclusions is extremely limited due to sparse data, heterogeneity
and risk of bias in the studies. Given this current synthesis, it is
not possible to advise a change in practice. While the evidence
is limited, it is important to note that these agents are available
directly to families without physician involvement in many coun-
tries. Therefore, these findings may be important to discuss with
families, to allow appropriate interpretation.
Implications for research
Given the concept above regarding the wide availability of many of
these agents direct to families, there is an urgent need to recognise
the increasing interest in this area and respond with appropriate
research that can truly inform and guide evidence-based practice.
Future studies need to use the full range of outcome measures
relevant to, and presented in, this synthesis of the existing evidence
consistently. Studies investigating the potential to reduce the onset
of new infantile colic should always report this as one of their
outcomes and be clear on the definition used to allow appropriate
comparison with previous studies. It may be prudent to report
the definition of colic using more than one diagnostic system to
resolve this concern.
Reporting of all adverse effects, those needing withdrawal, serious
adverse effects and particularly long-term safety follow-up are vital
to meaningfully move the evidence base forward.
Future studies focusing on specific patient groups, such as infants
with known aberrant gut flora, and specific probiotic strains are
also needed.Wider research investigating predictive factors for the
onset of colic would allow targeted prophylactic use.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baldassarre 2014
Methods Study design: double-blind, placebo-controlled, randomised trial
Unit: Obstetrics and Gynecology Unit, Department of Biomedical and Human Onco-
logical Science (DIMO), University of Bari
Location: Bari, Italy
Setting: outpatient
Participants Sample size: 67 mothers/term neonate pairs
Number of dropouts/withdrawals: 1 pair
Age: mothers = 33 years (mean); neonates = 39 weeks’ gestational age
Inclusion criteria: healthy, pregnant women at low obstetric risk
Exclusion criteria: pre-existing clinical conditions such as diabetes; hypertension; au-
toimmune disease; asthma; allergies; renal or hepatic diseases; viral, bacterial or proto-
zoan infection; anaemia; twin pregnancies; pregnancy disease and preterm deliveries;
smoking more than 10 cigarettes/day; use of other probiotics during the study protocol
Interventions Intervention (n = 33: 30 breastfed and 3 mix fed): high concentration, multi-strain
probiotic supplement, in packets. 900 billion viable lyophilised bacteria of 4 different
strains of lactobacilli (L paracaseiDSM 24733, L plantariumDSM 24730,L acidophilus
DSM 24735 and L delbrueckii subspbulgaricus DSM 24734), 3 strains of bifidobacteria
(B longumDSM 24736, BB breveDSM 24732 and B infantisDSM 24737) and 1 strain
of Streptococcus thermophilusDSM 24731
Control (n = 34: 29 breastfed and 5 mix fed; of which, 1 lost to follow-up): corn
starch
Duration of intervention: from 36 weeks’ gestation to 4 weeks postnatally
Outcomes Primary outcomes: analysis of breast milk for cytokine patterns, secretory IgA in breast
milk and stools, faecal lactoferrin
Secondary outcomes: safety, anthropometric data and gastrointestinal events (regurgi-
tation, bowel movements and colic symptoms following Rome III criteria in the neonatal
or toddler period)
Timings of measurements: within 72 hours after delivery and at day 30
Notes Study start date: April 2011
Study end date: December 2013
Declared DOI: none
Perceived DOI: none
Funding source: publication costs covered by NOPAIN Onlus Italian Association for
Pain Disease Treatment
Comment: the paper itself did not include all of this information, but the author was
able to supply further information in the form of a draft and now published report
(Baldassarre 2016).
Clinical trials record: NCT01367470
Risk of bias
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Baldassarre 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation performed using a
computer generated allocation sequence.”
Allocation concealment (selection bias) Low risk Comment: specifically mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: all participants, as well as sci-
entific and medical personnel dedicated to
the study and distributing the study agents
or assessing the samples and analyses were
blinded to group assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all participants accounted for;
1 infant in the placebo group was lost to
follow-up
Selective reporting (reporting bias) High risk Comment: colic was not stated to be an
outcome measure in the clinical trials reg-
istry record for this study, yet it was re-
ported in the paper
Other bias Low risk Comment: none noted
Indrio 2008
Methods Study design: double-blind, randomised study
Unit: Neonatology section of the Department of Pediatrics at the University of Bari
Location: Bari, Italy
Setting: inpatient and outpatient
Participants Sample size: 30 neonates
Number of dropouts/withdrawals: 0
Age: range 3-5 days
Inclusion criteria:healthy, appropriate-for-gestational age, preterm infants, with normal
APGAR scores
Exclusion criteria: respiratory distress, congenital malformation, inborn errors of
metabolism, or confirmed sepsis or infection
Interventions Intervention (n = 10 formula fed): 5 drops/day of L reuteri at a dose of 1 × 108 CFU/
day
Control (n = 20: 10 = exclusively breastfed (non-participants) and 10 = formula
fed): placebo
Duration of intervention: 30 days
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Indrio 2008 (Continued)
Outcomes Primary outcomes: number of episodes per day of regurgitation, vomiting and incon-
solable crying; and the number of evacuations per day
Secondary outcomes: assessment of gastric electrical activity, gastric emptying
Timings of measurements: day 4 and day 35 after birth
Notes Study start date: January 2006
Study end date: September 2006
Declared DOI: none
Perceived DOI: none
Funding source: supported by BioGaia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “were randomly assigned to IG [in-
tervention group] or CG [control group].”
Allocation concealment (selection bias) Low risk Comment: not mentioned. We contacted
the study author, through the interven-
tional agent supplier, who confirmed cen-
tral allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: none noted
Selective reporting (reporting bias) Low risk Comment: none noted
Other bias High risk Comment: supported by BioGaia, who
make the product.
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Indrio 2014
Methods Study design: prospective, multi-centre, double-blind, placebo-controlled, randomised
clinical trial
Unit: 9 paediatric units
Location: Italy
Setting: outpatients
Participants Sample size: 554 neonates
Number of dropouts/withdrawals: 86 (38 = intervention; 48 = control)
Age: 39 weeks’ gestational age
Inclusion criteria: gestational age > 37 to < 41 weeks, age < 1 weeks on entry into the
study, birth weight adequate for gestational age, APGAR score > 10 at 10 minutes, no
congenital disorders or clinical or physical alterations at clinical examination, and no
antibiotic or probiotic administration before inclusion
Exclusion criteria: those not meeting the above inclusion criteria
Interventions Intervention (n = 238): 5 drops/day of L reuteri DSM 17938 at dose of 1 × 108 CFU/
day, suspended in oil in a bottle with a dropper cap, given to neonates every day for 90
days
Control (n = 230): identical formulation of oils supplied in an identical bottle
Duration of intervention: 90 days
Outcomes Primaryoutcomes: reductionof daily crying time, regurgitation and constipation during
the first 3 months of life
Secondary outcomes: cost-benefit analysis of the probiotic supplementation with num-
ber of primary paediatrician visits; feeding changes; hospitalisations; access to a pae-
diatric emergency department; loss of parental working days; and use of simethicone,
cimetropium bromide and natural or herbal products to control gastrointestinal symp-
toms
Timings of measurements: 3 months
Notes Study start date: September 2010
Study end date: October 2012
Declared DOI: none
Perceived DOI: none
Funding source: supported by BioGaia, who make the product used in the study
Clinical trials record: NCT01235884
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “an independent statistician gener-
ated the random allocation sequence.”
Allocation concealment (selection bias) Low risk Comment: not mentioned. We contacted
the study author, through the interven-
tional agent supplier, who confirmed cen-
tral allocation concealment
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Indrio 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the study personnel, health care
workers, and parents were masked to the
study group allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Parents and investigators were
masked to the intervention.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: none noted
Selective reporting (reporting bias) Low risk Comment: none noted
Other bias High risk Comment: supported by BioGaia who
make the product.
Kukkonen 2008
Methods Study design: randomised, placebo-controlled, double-blind trial
Unit: none specified
Location: Helsinki, Finland
Setting: outpatient
Participants Sample size: 1018 infants
Number of dropouts/withdrawals: not reported but 939 completed the 6-month fol-
low-up and 925 completed the 2-year follow-up
Age: not reported
Inclusion criteria: pregnant women carrying children at increased risk of allergy re-
cruited from antenatal clinics
Exclusion criteria: < 37 weeks’ gestational age, twin baby, major malformation
Interventions Intervention (n = 468): pregnant women from 36 weeks took capsules containing a
mixture of Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve Bb99 and
Propiobibacterium freudenreichii ssp shermanii JS (8-9 × 109 CFUs in each capsule). For
6 months after birth, the infants received 1 opened capsule of the same probiotics and
0.8 g of galacto-oligosaccharides in liquid form daily
Control (n = 471): placebo
Duration of intervention: 4 weeks before delivery and 6 months after birth
Outcomes Primary outcomes: neonatal morbidity, infantile colic and defecation, feeding-related
behaviours (vomiting, constipation, excessive crying and abdominal discomfort)
Secondary outcomes: anthropometric measurement, infection, antibiotics and other
disease
Timings of measurements: 3, 6, 12 and 24 months
Notes Study start date: November 2000
Study end date: March 2003
Declared DOI: none
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Kukkonen 2008 (Continued)
Perceived DOI: none
Funding source: Helsinki University Central Hospital Research Funds and Valio
Clinical trials record: NCT00298337
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: randomised, double-
blind, placebo-controlled study with 2 par-
allel groups and computer-generated block
randomisation at 35 weeks’ gestation
Allocation concealment (selection bias) Unclear risk Comment: not mentioned. We contacted
the study author but received no response
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: none noted
Selective reporting (reporting bias) High risk Comment: while the manuscript men-
tioned a primary outcome of colic, it was
not explicitly stated in the trial registration
record
Other bias Low risk Comment: none noted
Pärtty 2013a
Methods Study design: randomised, double-blind, placebo-controlled trial
Unit: Department of Pediatrics, Turku University Hospital
Location: Turku, Finland
Setting: inpatient and outpatient
Participants Sample size: 94 preterm infants
Number of dropouts/withdrawals: 26 (28%) at 12 months of age
Age: 34.6 weeks (range 32-36 weeks) gestational age
Inclusion criteria: gestational age between 32 (+ 0) and 36 (+ 6) weeks, birth weight >
1500 g, and absence of any congenital defects in the gastrointestinal system or defects
preventing enteral nutrition
Exclusion criteria: infants not meeting the above inclusion criteria
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Pärtty 2013a (Continued)
Interventions Intervention (n = 62): prebiotic mixture (n = 31) of polydextrose and galacto-oligosac-
charides 1:1; 600 mg/day in 1 dose from day 1 to day 30 and 600 mg twice daily from
day 31 to day 60. Probiotics (n = 31) Lactobacillus rhamnosus GG (ATCC 53103) 1 ×
109 CFU/day in 1 dose from day 1 to day 30 and 1 × 109 CFU twice daily from day 31
to day 60
Control (n = 32): microcrystalline cellulose and dextrose anhydrate
Duration of intervention: 2 months
Outcomes Primary outcomes: frequency of crying, frequency of stools, consistency of stools
Secondary outcomes: analysis of gut microbiota
Timings of measurements: 1, 2, 4, 6 and 12 months of age
Notes Study start date: June 2008
Study end date: May 2011
Declared DOI: Mead Johnson provided part of 1 authors’ salary
Perceived DOI: none
Funding source:Mead Johnson
Clinical trials record: NCT00167700
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computerised block randomisa-
tion”
Allocation concealment (selection bias) Low risk Comment: specifically mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: specifically mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: specifically mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: none noted
Selective reporting (reporting bias) Low risk Comment: colic and adverse effects specif-
ically mentioned in both the trial registra-
tion record and the manuscript
Other bias High risk Comment: paid for by a specialist infant
milk manufacturer (Mead Johnson) who
provided the products and part of the salary
of 1 of the authors
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Vlieger 2009
Methods Study design: randomised controlled trial
Unit: 5 antenatal clinics in central part of the Netherlands
Location: Netherlands
Setting: outpatient
Participants Sample size: 159 neonates
Number of dropout/withdrawals: 33 dropouts (16 = intervention; 17 = control)
Age: 40.1 weeks’ gestational age = intervention, 39.9 weeks’ gestational age = control
Inclusion criteria: pregnant mothers who intended to bottle feed their infant from birth
onwards and mothers who stopped breastfeeding within the first week after birth, infant
had to be born at≥ 37 weeks’ gestation and had to be aged < 7days at time of enrolment
Exclusion criteria: use of antibiotics in the first week, congenital illnesses or malforma-
tions that could affect normal growth and insufficient knowledge of the Dutch language
Interventions Intervention (n = 69): standard formula supplemented with 1 × 107 CFU B animalis ssp
lactis/g (also known as Bifidobacterium Bb-12) deposited under American Type Culture
Collection (ATCC) number 27536 and 1 × 107 CFU L paracasei ssp paracasei/g (L casei
CRL-431, ATCC 55544)
Control (n = 64): standard, milk-based powder products supplemented with 0.24 g of
prebiotic galacto-oligosaccharides
Duration of intervention: 3 months
Outcomes Primary outcomes: safety and tolerance of formula containing probiotics, differences
in growth parameters at 3 months of age
Secondary outcomes: differences in growth parameters at 6 months of age, crying and
sleeping, stool characteristics, infant use of antibiotics, visits to general practitioner,
periods with signs of upper respiratory tract infections and gastrointestinal infections,
vomiting diarrhoea, constipation, colic, and rash or eczema
Timings of measurements: 1, 2, 3 and 6 months of age
Notes Study start date: November 2004
Study end date: January 2007
Declared DOI: 2 of the authors are employed by the sponsor, all other authors have no
conflict of interest
Perceived DOI: none
Funding source: Friesland Foods and 2 of the authors were employed by the sponsor
Clinical trials record: ISRCTN78225533
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: computer-generated random
number generator for concealment.
Allocation concealment (selection bias) Unclear risk Comment: not mentioned
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Vlieger 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: did not specifically state but
was implied.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: did not specifically state but
was implied.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: none noted
Selective reporting (reporting bias) Low risk Comment: none noted
Other bias High risk Comment: funded by a formula manufac-
turing company; 2 authors worked for the
company
APGAR: appearance, pulse, grimace, activity, respiration; CFU: colony-forming unit; DOI: declaration of interest(s); IgA: immunoglob-
ulin A; n: number of participants.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cekola 2015 Study did not investigate prevention of colic.
Di Mauro 2013 Conference abstract that did not describe an RCT.
Garofoli 2014 Study of regurgitation not crying.
Hoy-Schulz 2016 Not study of colic, and started at 4 weeks.
Mommaerts 2011 Review.
Olivares 2011 Conference poster abstract looking at safety of probiotics used prophylactically
Pärtty 2013b Research article, not an RCT.
Savino 2015 Study not examining colic.
Simone 2014 Not prophylactic.
Szajewska 2013 Not prophylactic.
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(Continued)
Wade 2001 Review of other studies, in Clinical Evidence.
Weizman 2006 Not from birth (from 4 months).
RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Probiotic preparation versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occurrence of new cases of colic:
random-effects model
3 1148 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.18, 1.19]
2 Occurrence of new cases of
colic: sensitivity analysis with
fixed-effect model
3 1148 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.38, 0.90]
3 Serious adverse effects 6 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Duration of crying
random-effects model
3 707 Mean Difference (IV, Random, 95% CI) -32.57 [-55.60, -9.
54]
5 Duration of crying: sensitivity
analysis with fixed-effect model
3 707 Mean Difference (IV, Random, 95% CI) -32.57 [-55.60, -9.
54]
6 Duration of crying: subgroup
analysis with term babies only
2 687 Mean Difference (IV, Random, 95% CI) -20.65 [-47.23, 5.
92]
7 Occurrence of colic: subgroup
analysis with pregnant women
2 1085 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.13, 2.20]
8 Mean duration of crying at study
end: random-effects model,
subgroup L Reuteri
2 574 Mean Difference (IV, Random, 95% CI) -44.26 [-66.60, -21.
93]
9 Mean duration of crying at study
end: sensitivity analysis with
fixed-effect model
2 574 Mean Difference (IV, Fixed, 95% CI) -40.53 [-46.53, -34.
52]
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Analysis 1.1. Comparison 1 Probiotic preparation versus placebo, Outcome 1 Occurrence of new cases of
colic: random-effects model.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 1 Occurrence of new cases of colic: random-effects model
Study or subgroup Probiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Baldassarre 2014 3/33 13/34 27.4 % 0.24 [ 0.07, 0.76 ]
Kukkonen 2008 20/506 20/512 39.2 % 1.01 [ 0.55, 1.86 ]
Pa¨rtty 2013a 5/31 16/32 33.4 % 0.32 [ 0.13, 0.77 ]
Total (95% CI) 570 578 100.0 % 0.46 [ 0.18, 1.19 ]
Total events: 28 (Probiotics), 49 (Placebo)
Heterogeneity: Tau2 = 0.50; Chi2 = 7.22, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours probiotics Favours placebo
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Analysis 1.2. Comparison 1 Probiotic preparation versus placebo, Outcome 2 Occurrence of new cases of
colic: sensitivity analysis with fixed-effect model.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 2 Occurrence of new cases of colic: sensitivity analysis with fixed-effect model
Study or subgroup Probiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baldassarre 2014 3/33 13/34 26.4 % 0.24 [ 0.07, 0.76 ]
Kukkonen 2008 20/506 20/512 41.0 % 1.01 [ 0.55, 1.86 ]
Pa¨rtty 2013a 5/31 16/32 32.5 % 0.32 [ 0.13, 0.77 ]
Total (95% CI) 570 578 100.0 % 0.58 [ 0.38, 0.90 ]
Total events: 28 (Probiotics), 49 (Placebo)
Heterogeneity: Chi2 = 7.22, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours probiotics Favours placebo
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Analysis 1.3. Comparison 1 Probiotic preparation versus placebo, Outcome 3 Serious adverse effects.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 3 Serious adverse effects
Study or subgroup Probiotics Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Baldassarre 2014 0/33 0/34 Not estimable
Indrio 2008 0/10 0/10 Not estimable
Indrio 2014 0/276 0/278 Not estimable
Kukkonen 2008 2/502 2/512 1.02 [ 0.14, 7.21 ]
Pa¨rtty 2013a 0/31 0/32 Not estimable
Vlieger 2009 0/69 0/64 Not estimable
0.01 0.1 1 10 100
Favours probiotics Favours placebo
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Analysis 1.4. Comparison 1 Probiotic preparation versus placebo, Outcome 4 Duration of crying random-
effects model.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 4 Duration of crying random-effects model
Study or subgroup Probiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min/day] N Mean(SD)[min/day] IV,Random,95% CI IV,Random,95% CI
Indrio 2008 10 32 (6) 10 88 (16) 33.9 % -56.00 [ -66.59, -45.41 ]
Indrio 2014 276 37.7 (33.8) 278 70.9 (51.9) 35.3 % -33.20 [ -40.49, -25.91 ]
Vlieger 2009 69 54 (42) 64 60 (54) 30.8 % -6.00 [ -22.53, 10.53 ]
Total (95% CI) 355 352 100.0 % -32.57 [ -55.60, -9.54 ]
Heterogeneity: Tau2 = 377.64; Chi2 = 26.89, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.77 (P = 0.0056)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours probiotics Favours placebo
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Analysis 1.5. Comparison 1 Probiotic preparation versus placebo, Outcome 5 Duration of crying: sensitivity
analysis with fixed-effect model.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 5 Duration of crying: sensitivity analysis with fixed-effect model
Study or subgroup Probiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Indrio 2008 10 32 (6) 10 88 (16) 33.9 % -56.00 [ -66.59, -45.41 ]
Indrio 2014 276 37.7 (33.8) 278 70.9 (51.9) 35.3 % -33.20 [ -40.49, -25.91 ]
Vlieger 2009 69 54 (42) 64 60 (54) 30.8 % -6.00 [ -22.53, 10.53 ]
Total (95% CI) 355 352 100.0 % -32.57 [ -55.60, -9.54 ]
Heterogeneity: Tau2 = 377.64; Chi2 = 26.89, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.77 (P = 0.0056)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours probiotics Favours placebo
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Analysis 1.6. Comparison 1 Probiotic preparation versus placebo, Outcome 6 Duration of crying: subgroup
analysis with term babies only.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 6 Duration of crying: subgroup analysis with term babies only
Study or subgroup Probiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min/day] N Mean(SD)[min/day] IV,Random,95% CI IV,Random,95% CI
Indrio 2014 276 37.7 (33.8) 278 70.9 (51.9) 53.9 % -33.20 [ -40.49, -25.91 ]
Vlieger 2009 69 54 (42) 64 60 (54) 46.1 % -6.00 [ -22.53, 10.53 ]
Total (95% CI) 345 342 100.0 % -20.65 [ -47.23, 5.92 ]
Heterogeneity: Tau2 = 327.44; Chi2 = 8.71, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours probiotics Favours placebo
Analysis 1.7. Comparison 1 Probiotic preparation versus placebo, Outcome 7 Occurrence of colic:
subgroup analysis with pregnant women.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 7 Occurrence of colic: subgroup analysis with pregnant women
Study or subgroup Probiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Baldassarre 2014 3/33 13/34 44.0 % 0.24 [ 0.07, 0.76 ]
Kukkonen 2008 20/506 20/512 56.0 % 1.01 [ 0.55, 1.86 ]
Total (95% CI) 539 546 100.0 % 0.54 [ 0.13, 2.20 ]
Total events: 23 (Probiotics), 33 (Placebo)
Heterogeneity: Tau2 = 0.83; Chi2 = 4.72, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours probiotics Favours placebo
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Analysis 1.8. Comparison 1 Probiotic preparation versus placebo, Outcome 8 Mean duration of crying at
study end: random-effects model, subgroup L Reuteri.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 8 Mean duration of crying at study end: random-effects model, subgroup L Reuteri
Study or subgroup Probiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min/day] N Mean(SD)[min/day] IV,Random,95% CI IV,Random,95% CI
Indrio 2008 10 32 (6) 10 88 (16) 48.5 % -56.00 [ -66.59, -45.41 ]
Indrio 2014 276 37.7 (33.8) 278 70.9 (51.9) 51.5 % -33.20 [ -40.49, -25.91 ]
Total (95% CI) 286 288 100.0 % -44.26 [ -66.60, -21.93 ]
Heterogeneity: Tau2 = 238.41; Chi2 = 12.08, df = 1 (P = 0.00051); I2 =92%
Test for overall effect: Z = 3.88 (P = 0.00010)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours probiotics Favours placebo
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Analysis 1.9. Comparison 1 Probiotic preparation versus placebo, Outcome 9 Mean duration of crying at
study end: sensitivity analysis with fixed-effect model.
Review: Probiotics to prevent infantile colic
Comparison: 1 Probiotic preparation versus placebo
Outcome: 9 Mean duration of crying at study end: sensitivity analysis with fixed-effect model
Study or subgroup Probiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min/day] N Mean(SD)[min/day] IV,Fixed,95% CI IV,Fixed,95% CI
Indrio 2008 10 32 (6) 10 88 (16) 32.1 % -56.00 [ -66.59, -45.41 ]
Indrio 2014 276 37.7 (33.8) 278 70.9 (51.9) 67.9 % -33.20 [ -40.49, -25.91 ]
Total (95% CI) 286 288 100.0 % -40.53 [ -46.53, -34.52 ]
Heterogeneity: Chi2 = 12.08, df = 1 (P = 0.00051); I2 =92%
Test for overall effect: Z = 13.23 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours probiotics Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Unused methods
Method Approach
Measurement of treatment effects Continuous data
When studies use different scales, we will calculate the standardised mean
difference (SMD) using Hedges’ g, and present it with 95% confidence
intervals
If some studies report an outcome as a dichotomous measure and others
used a continuous measure of the same construct, we will convert the
results for the former, the dichotomous measure, to a SMD
Cluster-randomised studies For each included study, we will determine whether the unit of analy-
sis is appropriate for the unit of randomisation and the design of that
study (i.e. whether the number of observations match the number of ran-
domised ’units’ (Deeks 2011)). The presence of cluster-randomised trials
is unlikely because such a design is uncommon in this field. However, if
we encounter such trials, we will use the intraclass correlation coefficient
(ICC) to convert trials to their effective sample size before incorporating
them into the meta-analysis, as recommended in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011b). If the ICC is not
available, we will use values from the published literature as an external
source, when available, as well as contacting the study authors and re-
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Table 1. Unused methods (Continued)
questing them to supply more data to allow calculation of an ICC esti-
mate (Campbell 2000).We will only use the ICC to calculate the effective
sample size or the effective SD for those cluster-randomised trials that do
not account for the cluster effects. We will label such studies with a C
Assessment of reporting bias If there aremore than 10 studies grouped in a comparison, wewill evaluate
whether reporting biases are present by using funnel plots to investigate
any relationship between effect estimates and study size or precision, or
both, as recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (Sterne 2011).
Due to the small number of studies expected, no formal test for plot
asymmetry is planned
Subgroup analysis and investigation of heterogeneity • Mode of delivery of baby (vaginal vs caesarean section).
• Short-term and long-term follow-up (< 4 weeks vs ≥ 4 weeks of
treatment).
• Low-quality trials vs high-quality trials (allocation concealment vs
lack of allocation concealment; blinding vs lack of blinding).
Sensitivity analysis We will conduct sensitivity analyses to determine whether findings are
sensitive to the following:
• bias, by restricting the analyses to studies judged to be at low risk of
bias for blinded assessment of the primary outcome;
• imputed data, by calculating the treatment effect including and
excluding the imputed data to assess whether this alters the outcome of
the analysis;
• dropouts and exclusions, by conducting worst-case vs best-case
scenario analyses;
• the definition of colic used, by conducting analyses on studies
using the stringent Wessel definition of infant colic (Wessel 1954), the
more recent definition given by Hyman 2006, and a non-recognised
definition.
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A P P E N D I C E S
Appendix 1. Definition of terms
Term Definition
Coliforms Coliform bacteria are an indicator of sanitary quality of foods and water. They ferment lactose with the
production of acid and gas. Coliforms can be found in the aquatic environment, in soil and on vegetation;
they are universally present in large numbers in the faeces of warm-blooded animals. While coliforms
themselves are not normally causes of serious illness, they are easy to culture, and their presence is used
to indicate that other pathogenic organisms of faecal origin may be present. Such pathogens include
disease-causing bacteria, viruses or protozoa and many multicellular parasites. Coliform procedures may
be performed in aerobic or anaerobic conditions
Dysmotility A condition in which muscles of the digestive system become impaired and changes in the speed, strength
or co-ordination in the digestive organs occurs. In the normal small intestine, liquefied food and secretions,
including digestive enzymes are pushed onwards by waves of muscular contraction
Enteritis Inflammation of the intestine, especially the small intestine, usually accompanied by diarrhoea
Microbiome The micro-organisms in a particular environment (including the body or a part of the body)
Microbiota Quote: “the ecological community of commensal, symbiotic and pathogenic microorganisms that literally
share our body space” (Lederberg 2001).
Necrotising enterocolitis A medical condition primarily seen in premature infants where portions of the bowel undergo necrosis
(tissue death). It occurs postnatally and is one of the most common causes of morbidity in premature
infants
Oligosaccharides A saccharide polymer (complex carbohydrate) containing a small number of simple sugars, which are not
digestible by humans, and instead function as prebiotics to support the growth of certain types of bacteria
in the gut
Paroxysms A sudden recurrence or intensification of symptoms such as a spasm or seizure. Also called paroxysmal
attacks
Appendix 2. Search strategies
Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library
Searched 3 June 2016 (276 records)
Searched 30 January 2018 (95 records)
#1[mh Colic]
#2colic*
#3((stomach or abdominal or abdomen*) near/3 (spasm* or pain* or cramp*))
#4((gastric or gastro*) near/3 (spasm* or pain* or cramp*))
#5[mh Crying]
#6(cry or crying or cries)
#7{or #1-#6}
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#8[mh infant]
#9(baby or babies or infant* or child* or newborn* or neonat*)
#10{or #8-#9}
#11[mh “Dietary Supplements”]
#12[mh “Complementary Therapies”]
#13[mh “Gastrointestinal Agents”]
#14[mh probiotics]
#15(probiotic* or synbiotic*)
#16[mh lactobacillaceae]
#17lactobac*ill*
#18[mh Bifidobacterium]
#19Bifidobacter*
#20Bifidus*
#21[mh Saccharomyces]
#22Saccharomyc*
#23[mh Streptococcus]
#24streptococc*
#25(Biogaia or Culturelle or Enflora* or Florastor or ((Gerber* or Nestle*) near/2 (Goodstart or Good Start)) or Nutramigen or VSL*3)
#26{or #11-#25}
#27#7 and #10 and #26 in Trials
MEDLINE Ovid
Searched 2 June 2016 (182 records)
Searched 30 January 2018 (71 records)
1 colic/
2 colic$.tw.
3 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
4 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
5 crying/
6 (cry or crying or cries).tw.
7 or/1-6
8 Dietary Supplements/
9 Complementary Therapies/
10 Gastrointestinal Agents/
11 probiotics/
12 (probiotic$ or synbiotic$).tw.
13 exp lactobacillaceae/
14 lactobac?ill$.tw.
15 exp Bifidobacterium/
16 Bifidobacter$.tw.
17 Bifidus$.tw.
18 exp Saccharomyces/
19 Saccharomyces$.tw.
20 Streptococcus/
21 streptococc$.tw.
22 (Biogaia or Culturelle or Enflora$ or Florastor or ((Gerber$ or Nestle$) adj2 (Goodstart or Good Start)) or Nutramigen or VSL?
3).tw.
23 or/8-22
24 exp infant/
25 (baby or babies or infant$ or child$ or newborn$ or neonat$).tw.
26 24 or 25
27 randomized controlled trial.pt.
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28 controlled clinical trial.pt.
29 randomi#ed.ab.
30 placebo$.ab.
31 drug therapy.fs.
32 randomly.ab.
33 trial.ab.
34 groups.ab.
35 or/27-34
36 exp animals/ not humans.sh.
37 35 not 36
38 7 and 23 and 26 and 37
MEDLINE In-Process & Other Non-Indexed Citations Ovid
Searched 2 June 2016 (44 records)
Searched 30 January 2018 (45 records)
1 colic$.tw,kw.
2 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw,kw.
3 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw,kw.
4 (cry or crying or cries).tw,kw.
5 or/1-4
6 (probiotic$ or synbiotic$).tw,kw.
7 lactobac?ill$.tw,kw.
8 Bifidobacter$.tw,kw.
9 Bifidus$.tw,kw.
10 Saccharomyces$.tw,kw.
11 streptococc$.tw,kw.
12 (Biogaia or Culturelle or Enflora$ or Florastor or ((Gerber$ or Nestle$) adj2 (Goodstart or Good Start)) or Nutramigen or VSL?
3).tw,kw.
13 or/6-12
14 5 and 13
15 (baby or babies or infant$ or child$ or newborn$ or neonat$).tw,kw.
16 14 and 15
MEDLINE Epub Ahead of Print Ovid
Searched 2 June 2016 (2 records)
Searched 30 January 2018 (3 records)
1 colic$.tw,kw.
2 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw,kw.
3 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw,kw.
4 (cry or crying or cries).tw,kw.
5 or/1-4
6 (probiotic$ or synbiotic$).tw,kw.
7 lactobac?ill$.tw,kw.
8 Bifidobacter$.tw,kw.
9 Bifidus$.tw,kw.
10 Saccharomyces$.tw,kw.
11 streptococc$.tw,kw.
12 (Biogaia or Culturelle or Enflora$ or Florastor or ((Gerber$ or Nestle$) adj2 (Goodstart or Good Start)) or Nutramigen or VSL?
3).tw,kw.
13 or/6-12
14 5 and 13
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15 (baby or babies or infant$ or child$ or newborn$ or neonat$).tw,kw.
16 14 and 15
Embase Ovid
Searched 2 June 2016 (1817 records)
Searched 30 January 2018 (81 records)
1 colic/
2 crying/
3 colic$.tw.
4 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
5 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
6 (cry or crying or cries).tw.
7 or/1-6
8 exp infant/
9 (baby or babies or infant$ or child$ or newborn$ or neonat$).tw.
10 8 or 9
11 7 and 10
12 Infantile colic/
13 11 or 12
14 diet supplementation/
15 alternative medicine/
16 gastrointestinal agent/
17 probiotic agent/
18 synbiotic agent/
19 (probiotic$ or synbiotic$).tw.
20 exp Lactobacillaceae/
21 lactobac?ill$.tw.
22 exp Bifidobacterium/
23 Bifidobacter$.tw.
24 exp Saccharomyces/
25 Saccharomyces$.tw.
26 exp Streptococcus/
27 streptococc$.tw.
28 (Biogaia or Culturelle or Enflora$ or Florastor or ((Gerber$ or Nestle$) adj2 (Goodstart or Good Start)) or Nutramigen or VSL?
3).tw.
29 or/14-28
30 Randomized controlled trial/
31 controlled clinical trial/
32 Single blind procedure/
33 Double blind procedure/
34 triple blind procedure/
35 Crossover procedure/
36 (crossover or cross-over).tw.
37 ((singl$ or doubl$ or tripl$ or trebl$) adj1 (blind$ or mask$)).tw.
38 Placebo/
39 placebo.tw.
40 prospective.tw.
41 factorial$.tw.
42 random$.tw.
43 assign$.ab.
44 allocat$.tw.
45 volunteer$.ab.
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46 or/30-45
47 13 and 29 and 46
CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature)
Searched 2 June 2016 (152 records)
Searched 30 January 2018 (62 records)
S1 (MH “Infant Colic”)
S2 (MH “Colic”)
S3 TI(colic*) OR AB(colic*)
S4 TI((stomach or abdominal or abdomen*) N3 (spasm* or pain* or cramp*)) or AB((stomach or abdominal or abdomen*) N3 (spasm*
or pain* or cramp*))
S5 TI((gastric or gastro*) N3 (spasm* or pain* or cramp*)) or AB((gastric or gastro*) N3 (spasm* or pain* or cramp*))
S6 (MH “Crying”)
S7 TI(cry or crying or cries) OR AB(cry or crying or cries)
S8 S2 OR S3 OR S4 OR S5 OR S6 OR S7
S9 (MH “Infant+”)
S10 TI(baby or babies or infant* or child* or newborn* or neonat*) or AB(baby or babies or infant* or child* or newborn* or neonat*)
S11 S9 OR S10
S12 S8 AND S11
S13 S1 OR S12
S14 (MH “Dietary Supplements”)
S15 (MH “Alternative Therapies”)
S16 (MH “Gastrointestinal Agents”)
S17 (MH “Probiotics”)
S18 (probiotic* or synbiotic*)
S19 (MH “Lactobacillus”)
S20 lactobac#ill*
S21 (MH “Bifidobacterium”)
S22 Bifidobacter*
S23 Bifidus*
S24 Saccharomyces*
S25 (MH “Streptococcus”)
S26 streptococc*
S27 (Biogaia or Culturelle or Enflora* or Florastor or ((Gerber* or Nestle*) N2 (Goodstart or Good Start)) or Nutramigen or VSL?3)
S28 S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
S29 S13 AND S28
PsycINFO Ovid
Searched 2 June 2016 (13 records)
Searched 30 January 2018 (2 records)
1 Crying/
2 colic$.tw.
3 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
4 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
5 (cry or crying or cries).tw.
6 or/1-5
7 (infancy 2 23 mo or neonatal birth 1 mo).ag.
8 (baby or babies or infan$ or child$ or neonat$ or newborn$).tw.
9 7 or 8
10 6 and 9
11 dietary supplements/
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12 Alternative Medicine/
13 probiotic$.mp.
14 synbiotic$.mp.
15 lactobac?ill$.mp.
16 Bifidobacter$.mp.
17 Bifidus$.mp.
18 Saccharomyces$.mp.
19 streptococc$.mp.
20 (Biogaia or Culturelle or Enflora$ or Florastor or ((Gerber$ or Nestle$) adj2 (Goodstart or Good Start)) or Nutramigen or VSL?
3).mp.
21 or/11-20
22 10 and 21
Science Citation Index - Expanded Web of Science (SCI-Expanded)
Searched 3 June 2016 (35 records)
Searched 30 January 2018 (138 records)
# 12 #10 AND #5
Indexes=SCI Timespan=2016-2018
# 11 #10 AND #5
Indexes=SCI Timespan=All years
# 10 #9 OR #8 OR #7 OR #6
Indexes=SCI Timespan=All years
# 9 Ts=(probiotic* or synbiotic*)
Indexes=SCI Timespan=All years
# 8 TS= (Gerber* or Goodstart or “Good Start”)
Indexes=SCI Timespan=All years
# 7 TS= (Biogaia or Culturelle or Enflora* or Florastor or Nutramigen or VSL*3)
Indexes=SCI Timespan=All years
# 6 TS =( Bifidobacter* or Bifidus* or lactobac*ill* or Saccharomyces* or streptococc* )
Indexes=SCI Timespan=All years
# 5 (#1 or #2 or #3) and #4
Indexes=SCI Timespan=All years
# 4 TS=(infant* or baby or babies or newborn* or neonat*)
Indexes=SCI Timespan=All years
# 3 TS=((stomach or abdominal or abdomen*) Near/3 (spasm* or pain* or cramp*))
Indexes=SCI T Timespan=All years
# 2 TS= ((gastric or gastro*) Near/3 (spasm* or pain* or cramp*))
Indexes=SCI Timespan=All years
# 1 TS=(colic* or cry or cries or crying)
Indexes=SCI Timespan=1970-2016
Social Sciences Citation Index Web of Science (SSCI)
Searched 03 June 2016 (2 records)
Searched 30 January 2018 (1 record)
# 12 #10 AND #5
Indexes=SSCI Timespan=2016-2018
# 11 #10 AND #5
Indexes=SSCI Timespan=All years
# 10 #9 OR #8 OR #7 OR #6
Indexes=SSCI Timespan=All years
# 9 Ts=(probiotic* or synbiotic*)
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Indexes=SSCI Timespan=All years
# 8 TS= (Gerber* or Goodstart or “Good Start”)
Indexes=SSCI Timespan=All years
# 7 TS= (Biogaia or Culturelle or Enflora* or Florastor or Nutramigen or VSL*3)
Indexes=SSCI Timespan=All years
# 6 TS =( Bifidobacter* or Bifidus* or lactobac*ill* or Saccharomyces* or streptococc* )
Indexes=SSCI Timespan=All years
# 5 (#1 or #2 or #3) and #4
Indexes=SSCI Timespan=All years
# 4 TS=(infant* or baby or babies or newborn* or neonat*)
Indexes=SSCI Timespan=All years
# 3 TS=((stomach or abdominal or abdomen*) Near/3 (spasm* or pain* or cramp*))
Indexes=SSCI Timespan=All years
# 2 TS= ((gastric or gastro*) Near/3 (spasm* or pain* or cramp*))
Indexes=SSCI Timespan=All years
# 1 TS=(colic* or cry or cries or crying)
Indexes=SSCI Timespan=All years
Conference Proceedings Citation Index - Science (CPCI-S) and Conference Proceedings Citation Index -
Social Science & Humanities (CPCI-SS&H); Web of Science
Searched 03 June 2016 (7 records)
Searched 30 January 2018 (7 records)
# 12 #10 AND #5
Indexes=CPCI-S, CPCI-SSH Timespan=2016-2018
# 11 #10 AND #5
Indexes=CPCI-S, CPCI-SSH Timespan=All years
# 10 #9 OR #8 OR #7 OR #6
Indexes=CPCI-S, CPCI-SSH Timespan=All years
# 9 Ts=(probiotic* or synbiotic*)
Indexes=CPCI-S, CPCI-SSH Timespan=All years.
#8 TS= (Gerber* or Goodstart or “Good Start”)
Indexes=CPCI-S, CPCI-SSH Timespan=All years
#7 TS=(Biogaia or Culturelle or Enflora* or Florastor or Nutramigen or VSL*3)
Indexes=CPCI-S, CPCI-SSH Timespan=All years
# 6 TS =( Bifidobacter* or Bifidus* or lactobac*ill* or Saccharomyces* or streptococc* )
Indexes=CPCI-S, CPCI-SSH Timespan=All years
# 5 (#1 or #2 or #3) and #4
Indexes=CPCI-S, CPCI-SSH Timespan=All years
# 4 TS=(infant* or baby or babies or newborn* or neonat*)
Indexes=CPCI-S, CPCI-SSH Timespan=All years
# 3 TS=((stomach or abdominal or abdomen*) Near/3 (spasm* or pain* or cramp*))
Indexes=CPCI-S, CPCI-SSH Timespan=All years
# 2 TS= ((gastric or gastro*) Near/3 (spasm* or pain* or cramp*))
Indexes=CPCI-S, CPCI-SSH Timesp.an=All years
# 1 TS=(colic* or cry or cries or crying)
Indexes=CPCI-S, CPCI-SSH Timespan=All years
LILACS (Latin American and Caribbean Health Science Information Database; lilacs.bvsalud.org/en)
Searched 6 June 2016 (7 records)
Searched 30 January 2018 (1 record)
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(tw:((colic* OR crying OR cries OR cry) AND (baby OR babies OR infant* OR neonat* OR newborn*))) AND (tw:((probiotic*
OR synbiotic* OR bifidobacter* OR bifidus* OR lactobac* OR saccharomyces* OR streptococc* OR biogaia OR culturelle OR
enflora* OR florastor OR nutramigen OR vsl* OR gerber* OR goodstart OR “Good Start”))) AND (instance:“regional”) AND ( db:
(“LILACS”))
Cochrane Database of Systematic Reviews (CDSR) part of the Cochrane Library
Searched 3 June 2016 (7 records)
Searched 30 January 2018 (5 records)
#1[mh Colic]
#2(colic*):ti,ab
#3[mh Crying]
#4(cry or crying or cries):ti,ab
#5{or #1-#4}
#6[mh infant]
#7(baby or babies or infant* or child* or newborn* or neonat*):ti,ab
#8{or #6-#7}
#9#5 and #8
#10[mh “Dietary Supplements”]
#11[mh “Complementary Therapies”]
#12[mh “Gastrointestinal Agents”]
#13[mh probiotics]
#14(probiotic* or synbiotic*):ti,ab
#15[mh lactobacillaceae]
#16(lactobac*ill*):ti,ab
#17[mh Bifidobacterium]
#18(Bifidobacter*):ti,ab
#19(Bifidus*):ti,ab
#20[mh Saccharomyces]
#21(Saccharomyc*):ti,ab
#22[mh Streptococcus]
#23(streptococc*):ti,ab
#24(Biogaia or Culturelle or Enflora* or Florastor or ((Gerber* or Nestle*) near/2 (Goodstart or Good Start)) or Nutramigen or VSL*3)
#25{or #10-#24}
#26#9 and #25 in Cochrane Reviews (Reviews and Protocols)
#27 #9 and #25 in Cochrane Reviews Published online June 2016 - January 2018 (Reviews and Protocols)
Database of Abstracts of Reviews of Effects (DARE) part of the Cochrane Library
Searched 3 June 2016 (5 records)
#1[mh Colic]
#2(colic*):ti,ab
#3[mh Crying]
#4(cry or crying or cries):ti,ab
#5{or #1-#4}
#6[mh infant]
#7(baby or babies or infant* or child* or newborn* or neonat*):ti,ab
#8{or #6-#7}
#9#5 and #8
#10[mh “Dietary Supplements”]
#11[mh “Complementary Therapies”]
#12[mh “Gastrointestinal Agents”]
#13[mh probiotics]
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#14(probiotic* or synbiotic*):ti,ab
#15[mh lactobacillaceae]
#16(lactobac*ill*):ti,ab
#17[mh Bifidobacterium]
#18(Bifidobacter*):ti,ab
#19(Bifidus*):ti,ab
#20[mh Saccharomyces]
#21(Saccharomyc*):ti,ab
#22[mh Streptococcus]
#23(streptococc*):ti,ab
#24(Biogaia or Culturelle or Enflora* or Florastor or ((Gerber* or Nestle*) near/2 (Goodstart or Good Start)) or Nutramigen or VSL*3)
#25{or #10-#24}
#26#9 and #25 in Other Reviews
Epistemonikos (www.epistemonikos.org)
Searched 6 June 2016. Limited to systematic reviews (26 records)
Searched 30 January 2018. Limited to systematic reviews added since 6 June 2016 (3 records)
(title:((title:(probiotic* OR synbiotic* OR Bifidobacter* OR Bifidus* OR lactobac*ill* OR Saccharomyces* OR streptococc*) OR
abstract:(probiotic* OR synbiotic* Bifidobacter* OR Bifidus* OR lactobac*ill* OR Saccharomyces* OR streptococc*))) OR abstract:
((title:(probiotic* OR synbiotic* Bifidobacter* OR Bifidus* OR lactobac*ill* OR Saccharomyces* OR streptococc*) OR abstract:
(probiotic* OR synbiotic* Bifidobacter* OR Bifidus* OR lactobac*ill* OR Saccharomyces* OR streptococc*)))) AND (title:(infant*
OR baby OR babies OR newborn* OR neonat*) OR abstract:(infant* OR baby OR babies OR newborn* OR neonat*)) AND (title:
(cry OR cries OR fussing OR colic OR stomach OR abdom* OR gastric OR gastro* OR cramp* OR spasm* OR pain*) OR abstract:
(cry OR cries OR fussing OR colic OR stomach OR abdom* OR gastric OR gastro* OR cramp* OR spasm* OR pain*)
WorldCat (www.worldcat.org/)
Searched 6 June 2016. Limited to dissertations and theses (4 records)
Searched 30 January 2018. Limited to dissertations and theses 2016-2018 (0 records)
kw:(colic* OR crying OR cries OR cry) ANDKW:(baby OR babies OR infant* OR neonat* OR newborn*) ANDKW:(probiotic* OR
synbiotic* OR bifidobacter* OR bifidus* OR lactobac* OR saccharomyces* OR streptococc* OR biogaia OR culturelle OR enflora*
OR florastor OR nutramigen OR vsl* OR gerber* OR goodstart OR “Good Start”)
ClinicalTrials.gov (www.clinicaltrials.gov/ct2/home)
Searched 6 June 2016 (95 records)
Searched 30 January 2018. Limited to: First posted after 6 June 2016 (11 records)
ADVANCED SEARCH Biogaia OR Culturelle OR Enflora* OR Florastor OR Nutramigen OR VSL* OR Gerber* OR Goodstart
OR “Good Start” | Child
OR
BASIC SEARCH (colic OR crying) AND (probiotics OR synbiotics)
WHO ICTRP (apps.who.int/trialsearch/Default.aspx)
Searched 6 June 2016 (44 records)
Searched 30 January 2018. Limited to: Received from 06 June 2016 (14 records)
Basic search
probiotics and colic OR probiotics AND crying OR synbiotics and colic OR synbiotics AND crying
Advanced search
Intervention: Biogaia OR Culturelle OR Enflora* OR Florastor OR Nutramigen OR VSL* OR Gerber* OR Goodstart OR “Good
Start”
Search for: clinical trials in children
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Recruitment status: All
Appendix 3. Criteria for assigning ’Risk of bias’ judgements
Sequence generation for randomisation
We only included RCTs in this review. We assessed randomisation as being at low risk of bias where the procedure of randomisation
sequence generationwas explicitly described (e.g. computer-generated randomnumbers, randomnumbers table or coin-tossing).Where
there was no description, we contacted the authors for further information, assigning a rating of unclear risk of bias when we received
no response. We would have considered studies that use non-randomised procedures (hospital number, date of birth) to have a high
risk of bias; however, this was not the case for any of the studies.
Allocation concealment
We assessed concealment of treatment allocation as being at low risk of bias if the procedure was explicitly described and adequate efforts
were made to ensure that intervention allocations could not have been foreseen in advance of, or during, enrolment (e.g. centralised
randomisation, numbered or coded containers or sealed envelopes). Procedures that we would have considered to have a high risk of
bias included alternation or reference to case record numbers or dates of birth, although there were no mention of these methods being
used in any of our included studies. Where there was no description of the method of allocation concealment, we contacted the study
authors, assigning a judgement of unclear risk of bias when we received no response.
Blinding of parents and health professionals
In this context, the intervention was administered by parents, so, in effect, we considered them the target of the blinding procedures.
Indeed, as the participants were under four months of age by the defined inclusion criteria (Criteria for considering studies for this
review), it was deemed that this item was not applicable to them. Furthermore, parents often acted as outcome assessors. We primarily
assessed the risk of bias associated with the blinding of parents of participants based on the likelihood that such blinding was sufficient
to ensure that parents had no knowledge of which intervention the infant received. If the study was open label, we assigned a judgement
of high risk of bias. If the study was reported with detail as blinded, we assigned a judgement of low risk of bias. If it was unclear, we
contacted the study authors, assigning a rating of unclear risk of bias when no response was received.
Blinding of outcome assessment
For each included study, we described the methods used, if any, to blind the outcome assessors from knowledge of which intervention
a participant received. We judged studies at low risk of bias if they blinded the outcome assessors, or where we considered that the lack
of blinding could not have affected the results. If blinding was not done or was not possible because of the nature of the intervention,
we judged the study at high risk of bias because it is possible that the lack of blinding influenced the results. If there was no description,
we contacted the study authors for more information, and if there was no response, we assigned a judgement of unclear risk of bias.
The blinding of health professionals was noted, if reported.
Incomplete outcome data
Incomplete outcome data essentially included attrition, exclusions and missing data.
We assigned a judgement of low risk of bias if:
• participants included in the analysis were exactly those who were randomised into the trial; missing outcome data were balanced
in terms of numbers across intervention groups, with similar reasons for missing data across groups or if there were no missing
outcome data;
• for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not sufficient to
have a clinically relevant impact on the intervention effect estimate;
• for continuous outcome data, the plausible effect size (SMD) among missing outcomes was not sufficient to have a clinically
relevant impact on the observed effect size; or
• missing data were imputed using appropriate methods.
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We assigned a judgement of high risk of bias when:
• reasons for missing outcome data were likely to be related to the true outcome, with either an imbalance in numbers or reasons
for missing data across intervention groups;
• for dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk was sufficient to
induce clinically relevant bias in the intervention effect estimate;
• for continuous outcome data, the plausible effect size (SMD) among missing outcomes was sufficient to induce clinically
relevant bias in the observed effect size;
• an ’as-treated’ analysis was carried out in cases where there was a substantial departure of the intervention received from that
assigned at randomisation; or
• there was a potentially inappropriate application of simple imputation.
We assigned a judgement of unclear risk of bias when:
• there was insufficient reporting of attrition or exclusions, or both, to permit a judgement of low or high risk of bias;
• the study reported incomplete outcome data; or
• the trial did not clearly report the numbers randomised to intervention and control groups.
Selective outcome reporting
We assessed the reporting of outcomes as being at low risk of bias if the results of the trial reported all of the study outcomes declared in
the trial’s methods section. We also evaluated whether different reports of the study were available, including protocols, and examined
them to ensure that there was no suggestion of selective outcome reporting. If there was no description, we contacted the authors for
more information, and if we did not receive a response, we assigned a judgement of unclear risk of bias. When there was evidence of
selective reporting (deviation from protocol, key planned outcomes not reported), we assigned a judgement of high risk of bias.
Other potential threats to validity
When the study was at risk of other sources of bias not captured by the above domains, we assessed it at high risk of bias; for instance, if
the study was stopped early due to a data-dependent process, had a baseline imbalance between the groups or its sources of sponsorship
or funding. We assessed the study at low risk of bias if it appeared to be free from such threats to validity. When the risk of bias was
unclear from the published information, we attempted to contact the study authors for clarification. When this was not forthcoming,
we assessed these studies as being at unclear risk of bias.
C O N T R I B U T I O N S O F A U T H O R S
TGO: contributed to data extraction, ’Risk of bias’ assessment, analysis and full write-up of the review.
MG: conceived the project; cosearched, screened and reviewed full-text reports; extracted data; judged the risk of bias and certainty of
the evidence; analysed the data; and cowrote the manuscript.
SSCB: cosearched, screened and reviewed full-text reports; extracted data; judged the risk of bias and certainty of the evidence; analysed
the data; and cowrote the manuscript.
MRT: is the named correspondent. MRT reviewed the final protocol and review, and contributed to the text and analysis.
AA: reviewed the final protocol and review, and contributed to the text and analysis.
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D E C L A R A T I O N S O F I N T E R E S T
TGO: none.
MG is employed by Blackpool Victoria Hospital (NHS) and declares that he received some financial support from the Trust to employ
a Research Assistant; however, they had no involvement in the planning or execution of this review. MG has received travel grants from
2016 to 2019 from Ferring and BioGaia to attend scientific meetings and these companies produce treatments for colic that may be
tested in this study. MG declares that these companies had no involvement in the planning, design or conceptual planning of this study.
MG has received travel grants from Tillotts Pharma and Synergy Pharmaceuticals to attend meetings to present the results of previous
works. They have had no input or involvement in any aspect of the review process during this or previous systematic reviews carried
out by MG, such as Bowel preparation for paediatric colonoscopy (Gordon 2012) and Probiotics for maintenance of remission in ulcerative
colitis (Naidoo 2011).
SSCB is being paid as a Research Assistant for this review from Blackpool Teaching Hospitals NHS Foundation Trust*. SSCB is
Chair of the Local Infant Feeding Information Board (LIFIB), which produces evidence-based information on infant feeding topics for
health professionals. SSCB is a self-employed Infant Feeding Information Specialist and provides expertise in infant feeding, writing
briefing papers and newsletters, etc., and delivering workshops across the northwest of England. This is for the LIFIB and the Sudden
Unexpected Death of a Child Prevention Team in Lancashire. Money fromLancashire County Council, via The BreastfeedingNetwork,
funds the latter, and work related to this is paid for by the hour. SSCB is self-employed as an International Board Certified Lactation
Consultant in private practice. SSCB is a Committee Member of the main Lactation Consultants of Great Britain (LCGB) Committee
and Chair of the Communications Team. She is also Chair of the committee for the Breastfeeding Festival, which puts on one × two-
day event each year to celebrate breastfeeding and provide interesting and educational speaker sessions on infant feeding. All of these
positions are unfunded and voluntary but travel expenses are paid. SSCB declares that she was a Lay Member on the National Institute
for Health and Care Excellence (NICE) Guideline Committee on Faltering Growth in Infants and Children from 2015 to 2017 for
which she was paid an honorarium by NICE. She also declares that she is a trustee of the UK Association of Milk Banking; an unfunded
position with travel expenses up to twice a year, and sometimes accommodation at conferences to run stalls etc. are paid. SSCB declares
that neither she personally nor any of the entities that she represents take funding of any kind from any commercial interests in infant
feeding or early years, and that she works completely within the professional code of ethics as an International Board Certified Lactation
Consultant.
MRT has been part of an advisory board for Roche related to a study for people with Down’s syndrome about improving cognition.
MRT was reimbursed for her travel costs, and her Trust received fees for her time. MRT confirms that she has not received any fees
from any other commercial sources from 2015 to 2018.
AA: none.
*Disclaimer: MRT, MG, TGO are members of staff of the Blackpool Victoria Hospital. The authors alone are responsible for the views
expressed herein; they do not necessarily represent the decisions, policy or views of the NHS or Department of Health.
S O U R C E S O F S U P P O R T
Internal sources
• Blackpool Teaching Hospitals NHS Foundation Trust, UK.
Blackpool Teaching Hospitals is the employer of three review authors: MG and MT are employed in the medical team for the
hospital, and SB was employed by the hospital as a Research Assistant for 12 months.
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External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• Changes to authorship: Chris Wallace, who contributed to the development of the protocol (Banks 2016), was replaced by Teck
Ong.
• Objectives. We modified the ’Objectives’ to make it more concise.
• Types of studies. For added clarity, we specified that cluster and cross-over trials were eligible for inclusion.
• Types of interventions. In the protocol, Banks 2016, we stated that in order to be included in the review a study would have to
focus on the effect of the intervention on infantile colic. Before completing the screening, and after discussion within the author
group, we decided that we would include studies where the infants were asymptomatic and the study considered the onset of colic,
even if it was not the main focus of the study. Given that the prophylactic use of these drugs in almost all trials considered a number
of outcomes, we felt this was reasonable.
• Primary outcomes. The primary outcome measure ’reduction in the duration of crying’ in the published protocol (Banks 2016),
was, in fact, not appropriate. As by definition all babies included in studies at baseline did not have infantile colic, reduction in crying
is not an appropriate primary outcome and was subsequently replaced, prior to data extraction, with the primary outcome
’occurrence of new cases of colic at study end, as defined by the Wessel criteria’.
• Secondary outcomes. We reworded the outcomes of ’reduction in the duration of crying’ and ’reduction in frequency of crying
episodes per 24 hours’, to the following more neutral formulations, to reflect the fact that we are assessing the variable rather than a
deterioration in the variable: ’duration of crying’ and ’frequency of crying episodes per 24 hours’.
• ’Summary of findings’ tables. We updated the GRADE criteria in line with current guidance, to refer to ’certainty’, instead of
’quality’ (high certainty, moderate certainty, low certainty and very low certainty).
• Subgroup analysis and investigation of heterogeneity. It became clear that there were a number of included papers that started
administering treatments to pregnant women and continuing this in some form postnatally. This was not a form of study that was
expected and therefore a further subgroup analysis was added to explore the impact of this particular approach.
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